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ABSTRACT 
We previously demonstrated that interleukin- I (IL-1) and tumor necrosis factor 
(TNF) activities only partially account for calvarial bone resorption induced by local 
application of lipopolysaccharide (LPS) in mice. The present study was undertaken to 
determine the role and relative contribution of IL-11 and prostaglandin(s) (PGs) in 
LPS-induced bone resorption in vivo. One-time dose of LPS was injected into the 
subcutaneous tissue overlying the calvariae of IL-lRi- 1- TNFRp5S-1--IL-1Rl _1_ and 
wild-type mice. Mice were then treated with injections of anti-It -11 monoclonal 
antibody (mAb ), indomethacin or PBS and sacrificed 5 days later. Histological 
sections stained for TRAP were quantified by histomorphometric analysis. At low 
dose of LPS (100 µg/mouse), the percentage of bone surface covered by osteoclasts 
was found similar in three strains of mice. The increase was reduced by 50% with 
anti-IL-11 mAb and by 60% with indomethacin. At higher doses of LPS (500 
µg/mouse), we found an 8-fold increase in wild type and 5-fold in IL-lRl _1_ and 
TNFRp55-1--IL-1Rl _1_ mice after normalizing with the value from saline+PBS control 
group in the same strain of mice. The increase was reduced by 63 and 78% in wild-
type mice, and by about 73 and 84% in IL-lRi- 1- and TNFRp5S-1--IL-1R1_1_ mice 
treated with anti-IL-11 mAb or indomethacin respectively. Our findings suggest that 
in vivo at low-dose (100 µg/mouse), LPS-induced bone resorption is mediated 
vi 
by IL-11 and PGs, while at high LPS dose ( 500 µg/mouse ), it is mediated by IL-
11, PGs, IL-1 and TNF signaling. IL-11 and PGs mediate LPS-induced bone 
resorption by enhancing osteoclastogenesis independently of the IL-1 or TNF 
signaling. 
vii 
INTRODUCTION 
Bone resorption is a feature of chronic inflammatory diseases such as rheumatoid 
arthritis, osteomyelitis, bacterial arthritis and periodontitis (Nair, S. Meghji, 1996). The 
periodontitis is a common inflammatory disorder that often leads to irreversible alveolar 
bone resorption and tooth loss among adults, and is characterized as a peripheral infection 
involving species of Gram-negative organisms (Taubman, M. 2001 ). The key issue to be 
addressed in these diseases is how bacteria cause pathological bone loss. 
Lipopolysaccharide (LPS), a component of the outer membranes of all Gram-negative 
bacteria (Rietschel, E. 1992), was the first bacterial component shown to be capable of 
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inducing bone resorption in vitro ( Nair, S. Meghji, 1996). Although LPS has been 
identified as a major bacterial bone resorbing factor, the cellular mechanism by which 
LPS stimulates bone resorption has not been fully elucidated. Thus, understanding the 
means by which LPS enhances bone resorption would provide an effective therapeutic 
strategy to prevent and treat bacterially induced bone resorption. 
It is known that LPS triggers inflammatory process, both locally and systemically, 
and stimulates cytokine secretion ( Nair, S. 1996, Tobias, P. 1997). LPS may stimulate 
host cells, including gingival fibroblasts, fibroblastic cells in the periodontal ligament, 
recruited leukocytes (monocytes and macrophages) or osteoblasts producing cytokines 
and local mediators (Shinar, D. 1990 Taubman, M. 2001). The major effects of LPS are 
produced by mediators ( e.g. LPS-binding proteins, cytokines, prostaglandins, 
prostacyclins, NO etc.). But the signal pathway by 
which LPS stimulates bone resorption is unclear. Our previous study (Chiang, C.,Amar, 
S. 1999 ) demonstrated the existence of two signal pathways in LPS-induced bone 
resorption in vivo: one at high LPS doses and one at low LPS doses. At higher 
concentrations of LPS, osteoc _lastogenesis and bone resorption are substantially mediated 
by interleukin- I (IL-1) and tumor necrosis factor (TNF) receptor signaling, but these 
signaling do not completely account for bone resorption at lower LPS concentrations. At 
lower LPS concentrations, additional mediators, working independently or in concert 
with IL-1 and TNF, appear to contribute to LPS-induced bone resorption in vivo. The 
present work is a follow-up of our previous study advocating for the role 6f interleukin-
11 (IL-11) and prostaglandin(s) (PGs) with IL-1 and TNF in LPS-induced bone 
resorption in an in vivo model. 
IL-11, a 178-amino-acid nonglycosylated peptide cytokine critical for osteoclast 
development (Girasole, G. 1994), was initially isolated from a bone marrow-derived 
stromal cell line (Paul, S. R., F. Bennet, J. 1990). IL-11 belongs to a family of cytokines 
including IL-6, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and 
cardiotrophin 1, all of which signal through gpl30 (Kishimoto, T. 1995). IL-11 is not 
produced by monocytes or lymphocytes. Its expression is restricted to certain cells of the 
mesenchymal lineage, such as bone marrow stromal cells, osteoblasts (Romas, E. 1996), 
articular chondrocytes, synoviocytes, lung fibroblasts, (Maier, R. 1993) and osteosarcoma 
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cells (Elias, J. 1995). IL-11 receptor transcripts have been demonstrated on mature 
osteoclasts and osteoblasts in bone marrow cultures, (Romas, E. 1996) and on 
osteoblastic and chondroblastic progenitor cells during mouse embryogenesis (Neuhaus, 
H. 1994). Current research demonstrated that IL-11 stimulates multinucleated osteoclast-
like cell formation and bone resorption in a dose-dependent manner in cell and organ 
culture systems (Hill, P. A., A. Tumber, S. 1995). PGs are ubiquitous local hormones that 
have long been known to exert important effects on the skeleton (Raisz, L. 1984) and in 
immuno-inflammatory responses. Extensive clinical research over many years has also 
demonstrated a significant role of PGs in the pathogenesis of peri dontal disease (Lader, 
C. 1998 S., Offenbacher, C. 1986). 
Elevated PGE2 levels within the gingival crevicular fluid have been suggested as a 
reliable biochemical marker for periodontal disease activity and severity (Offenbacher, S. 
1986). PGs are produced as the metabolites from arachidonic acid by two key enzymes, 
cyclooxygenase-1 and cyclooxygenase-2. Cyclooxygenase-1 is produced constitutively in 
many tissues and appears to represent an essential component of tissue homeostasis. In 
contrast, cyclooxygenase-2 is generally undetectable under physiological conditions and 
appears to be responsible for PGs in inflammation. lndomethacin is a relatively 
nonselective inhibitor of both types of cyclooxygenase (Willaiams, R. C. 1999), and has 
been widely used in in vitro and in vivo studies. 
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Interestingly, the systematic role and relative contribution of IL-11 and PGs 
( compared to TNF and IL-1) in the regulation of LPS-induced bone resorption in vivo 
remains unknown. Therefore, by using anti-IL-11 monoclonal antibody (mAb) and 
indomethacin, we investigated in the present study the relative role of IL-11 and PGs in 
the overall process of bone resorption at high and low dose of LPS in three strains of 
mice. Our data indicated that IL-11 and PGs are significant mediators of LPS-induced 
osteoclastogenesis and bone resorption in vivo, and that they may act independently of 
IL-1 and TNF receptor signaling. 
4 
Literature review 
Periodontal disease are consider Gram-negative bacterial infection of the periodontuim 
because of the bacterial etiology, an immune response, and tissue destruction. Tissue 
destruction includes alveolar bone resorption, collagen digestion, and periodontal pocket 
formation, which result from apical migration of the junctonal epithelium (JE) along the 
root surface. Alveolar bone destruction, which elicits eventual exofoliation of the teeth , 
is cused by bacterial plaque-derive substance ( directly or indirectly) throughout 
stimulation of the host response (Williams, 1990). Among the multiple pathogen derived 
virulence components, LPS is belived to play a major role by inducing host cells to 
release proinflammatory mediators. 
I. Bone cell biology 
1. Formation and structure of the bone tissue 
The formation, growth, maintenance, and healing of the skeleton require that bone be 
formed throughout life. Normal osteoblasts produce bone under a variety of conditions, 
including embryonic development, bone growth and remodeling, myositis ossification or 
heterotopic ossification following soft tissue trauma or a fracture and in response to 
neoplasms and infections. Bone matrix is formed by the deposition of type I collagen 
fibers, which compose 90% of, total matrix proteins in the bone. Crystals of 
hydroxyapatite are found on the collagen fibers, within them, and in the ground 
sustenance. The ground substance is essentially compose of glycoproteins and 
proteoglycans. These highly anionic complexes have a high ionbinding capacity and 
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probably play an important part in the calcification process and the fixation of the 
hydroxyapatite crystals to the collagen fibers (Baron 1993) 
Noncollagenous proteins (NCPs) comprise of 10-15% of the total bone protein 
content. Most of these proteins are synthesize by bone forming cell ( osteoblasts) which 
mainly synthesize fibronectin (FN), thrombospondin (TSP), osteopontin(OP), and bone 
sialoprotein. The most abundant NCP produced by bone cells is osteonectin, a 
phosphorylated glycoprotein accounting for about 2% of the total developing bone. Its 
function in bone is potentially associated with osteoblast growth and proliferation 
(Termine, 1993). 
Proteoglycans are macromolecules that contain acidic po ysaccharide 
side chains attached to a central core of protein. These are two glycosaminoglycans, one 
is chondrotin sulfate, which may be important in maintaining the integrity of cell 
membrane, and the other is heparin sulfate, which facilitates interaction of the osteoblast 
with extracellular macromolecules and heparin-binding growth factors. 
A. Endochondral formation 
The Endochondral ossification that leads to the formation of embryonic long bones 
begins with the aggregation of undifferentiated cell that secrete a cartilaginous matrix and 
differentiated into chondroblast. After formation of hyaline or hyaline-like cartilage, a 
periostal covering appears around the diaphphysis and begins to form a thin collar of 
bone. At least some regions of the cartilage matrix mineralized, the chondrocytes enlarge, 
vascular buds invade the cartilage , and invading cell resorb the central portion of the 
cartilage creating marrow cavity. Osteoprogenitor cells accompanying the vascular buds 
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differentiate into osteoblasts then resorb the calcified cartilage and immature bone, and 
osteoblast replace the mixture of calcified cartilage and immune bone with mature 
lamellar bone. 
B. Intramembranous formation 
In contrast to enchondral ossification , no cartilaginous model forms in the region of 
intramembranous formation of bone. The aggregation of undifferentiated mesenchymal 
cells into layers of membranes initiate this process. These cells synthesize a loose 
organic matrix that often contains blood vessels, fibroblast, and Osteoprogenitor cells. 
The Osteoprogenitor cells differentiated into osteoblast and deposit spicules and islands 
of organic bone matrix that then mineralized. Osteoblasts cover the surface of the 
\ 
spicules and island and rapidly add new bone matrix. 
C. Appositional formation 
Appositinal formation of the bone occurs during periosteal enlargement of bones and 
during bone modeling and remodeling. Unlike Endochondral or ~ntramembranous 
formation, appositional formation begins with the alignment of osteoblast on an existing 
bone surface. These cells then synthesize osteoid, often in successive layers that form 
bone lamellae. During development and growth of the skeleton, periosteum covers the 
osseous primordia formed by Endochondral or intramembranous ossification soon after 
the appearance of the first ossification center. 
2. Coupling of bone formation and ~esorption 
After the initial ossification of the embryonic skeleton, osteoblast and osteoclast begins 
modeling and remodeling each bone. In general, modeling refers to alterations in the 
shape of the bone, whereas remodeling refers to turnover of bone that dose not alter the 
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shape; however the two process often occur simultaneously and the distinction between 
them may not be readily apparent. A central point in this mechanism is the production of 
specific proteinases by cells of the osteoblast lineage and their regulation by hormones 
and paracrine factors. Collgenase activity of cultured of bone I production solely by 
osteoblast and is secreted in an inactive form that must be activated by proteolysis. 
Osteoblasts also produce tissue plasminogen activator (tPA) the activity of which is 
stimulated by bone resorbign hormones. PA converts plasminogen to plasmin, which is 
known to be capable of activating latent collagenase. This led to proposal that hormone 
regulated tP A has the function of generating plasmin to activate latent collagenase, which 
could then either contribute to matrix breakdown or else remove the thin layer of collagen 
separating osteoclast from mineral (Chamber and Fuller ,85) 
the activity of these proteolytic enzymes in the environment of osteoblast and 
osteoclast and their control by the number of circulation and local factor seems likely to 
be important in determining communicating between cells. TGF-B produced by 
osteoblast and released from matrix in the process of osteoblastic resorption is also 
important in these processes. (Lund and Riccio,87) 
A. osteoblast formation and differentiation 
Circulating hormones and locally generated factors contributes to the control of the 
formation , differentiation, and development of mature osteoblast and osteoclast. 
the term osteoblast describes a lineage of cells that differ substantially in their 
properties at different stages of development. Although there is still much discussion of 
what constitutes " osteoblast phenotype" members of the lineage at various stage are only 
likely to express a proportion of the total feature associated with the phenotype. Much 
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information derived from the usage or clonal osteosarcoma cell lines (Partridge, 1983). It 
was the initial studies of these clonal line that indicate the likelihood that heterogeneity 
exist among cells even within the osteoblast lineage. This has since been confirmed by 
further studies of clonal population from bone (Sudo H, 1983 ). Direct effects o PTH on 
replication of osteoblast have been shown in several systems, including stimulation of 
growth of clonal osteosarcoma cells at low doses of PTH, followed by inhibition at 
higher doses. In osteoblast-rich culture, PTH was shown to promote proliferation. The 
general conclusion from studies of effects of PTH and calcitriol in several system is that 
they are clearly able to influence proliferation of osteoblast or precursors, and the 
direction of effects may have depended on the stage of differentiation of the target cells. 
B. Histological and morphological characteristics of osteoblast 
Histological characteristics of the osteoblast reflect a very metabolically active cells. 
The cell is polarized with organelles grouped on one side and an extensive network of 
rough endoplasmic reticulum. The nucleous is usually found in the cytosol at the opposite 
side of the cell. There are usually present one to three nucleuos. Golgi apparatus is 
positioned between the nucleous and rough endoplasmic reticulum. This is well develop 
to produced large amount of type I collagen. Another characteristic is the presence of 
substantial amount of the enzyme, alkaline phosphate. Bone-specific alkaline has been 
localized in the plasma membrane of osteoblast, but its true function has not been 
identified (Puzas 1993). 
C. osteoclast formation and differentiation 
Osteoclasts are formed by the fusion of mononuclear precursors. Previously, it 
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was considered that osteoclasts are derived from a common mesenchymal precursors or 
even those osteoclasts are derived from or give rise to osteoblasts. Some evidence 
suggests Those osteoclasts are originate from extraskelatal blood borne precursors 
There are three model which are proposed by Mundy in 1993 the first model 
suggest that the hematopoietic stem cells give rise to osteoclast. Second, CFU-GM gives 
rise to moncytes and mature monocyte-macrophage that can form osteoblast. In a third 
models, the hematopoitic stem cells give rise to a unique stem cell, CFU-O, the osteoclast 
colony- forming cell that is distinct from cells of the granulocyte-macrophage lineage. 
This cell then differentiated and fuses to form mature osteoclast. 
The development of osteoclasts from stem cells through precursors to the 
multinucleated osteoclast is a complex multi-step process. It must require the initial 
action of colony-stimulating factors, followed by the enhancing effects of PT A, PGE2 
calcitriol, and TGF-a and the inhibitory effects of calcitonin and interferon. TGF-b has 
also been shown to be a potent inhibitor of multinucleated cell formation in human bone 
marrow culture. 
D. Histological and morphological characteristics of osteoclast 
The osteoclast is a highly specialized multinucleated cell whose primary function is to 
help in the control of calcium homeostasis. The osteoclast is the extremely large cell. The 
average size is 50to 100 um, and may contain 2 and 100 nuclei per cell. The osteoclast is 
located on endosteal bone surface, within the Haversian system and on periosteal surface 
beneath periosteum. The characteristic ruffled border that forms at the site between where 
the osteoclast is attached to the bone matrix is a convolution of plasma membrane with 
many long cytoplasmic processes. The plasma membrane is closely opposed to the bone 
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surface with an adjacent organelle free zone, clear zone, which is rich in actinlike 
filament. Other ultrastructural characteristic of osteoclasts includes large number of 
lysosomes, numerous pleomorphic mitochondria, and extensive Golgi complex located 
around the nucleus. Dense granules and prominent vesicles in the region of ruffled border 
characterize their cytoplasm. 
Histochemical studies have shown that osteoclast contains a tartrate-resistant acid 
phosphate activity that is found in lysosmes , Golgi complex, extracellular channels of 
ruffled border, and the space between cells and bone. tartrate-resistant acid phosphate 
appears to be a marker for osteoclast in bone section and been proposed as a good marker 
of osteoclast formed in murine marrow cultures.( Roodman 1991) 
3. Modulation of osteoclastogenesis and signals for bone resorption 
The developments of osteoclasts consist of several stages: differentiation of the 
progenitors into mononuclear osteoclast , survival and fusion of mononuclear osteoclasts 
to form multinucleated osteoclast and activation of osteoclast to resorb the bone. 
Osteoclast differentiation factor (ODF) and M-CSF are indispensable for differentiation 
of osteocalst progenitors to osteocalst. When osteoblast/stromal cells are removed from 
cocultures, osteoclast died within 48 hours via spontaneous occurring apoptosis (Jimi, E 
Shuto 1995). This observation suggests that some cytokines produced by 
osteoblast/stromal cells are essential for he survival of osteoclasts. Tsukii et. al 
established that ODF plays a critical role in bone resorption induced by various bone 
resorbing factors in the microenvironment of bone. ODF most likely activates osteoclast 
to resorb bone in this system. Taken together with the findings that ODF expression in 
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osteoblastic cell is upregulated by various bone resorbing factors,(Y asuda, 1998), these 
result suggest that the simulation of bone resorption with these factors is mediating 
through upregulating of ODF expression on the membrane of osteoblast/stromal cell. 
Lacey et. al in 1998 showed that the hypercalcemic effects of ODF in mice, which is a 
minor image of the hypercalcemic effect of OPG/OCIF, together with ODF mediated-
bone resorption in the organ culture, suggest that ODF supports the survival and 
activation of osteoclast to resorb the bone in vivo. These observations also raise the 
possibility that systems hormones, such as 1,25 (OH) 2D3 and PTH, strictly control serum 
calcium level through modulation of bone resorption by ODF and OPG/OCIF in the 
microenvioroment of bone. 
Recent molecularly cloned ODFR from cDNA expression library of mouse osteoclast 
progenitor revealed that ODFR is identical to RANK, an identical member of TNF 
receptor family, which is involved in the regulation of dendritic cell function. Namely, 
anti-RANK antibody mimicked the ODF function suggesting that the clustering of 
RANK is required for ODF-RANK-mediated signaling for osteoclastogenesis 
(Nakagawa, 1998). 
II. Receptor-dependent mechanisms of lipopolysaccharide 
(LPS) induced cytokines 
Lipopolysaccharide (LPS, endotoxin), a major constituent of the outer membrane of 
Gram-negative bacteria, causes a variety of pathophysiological effects in experimental 
Animals and in humans. These effects are not direct but induced by the interaction of 
LPS with the membrane of target cells. Cells of the mononuclear phagocytic system, B-
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lymphocytes, granulocytes, platelets, fibroblast, and endothelial cells are primary target 
cells of LPS. As a consequence of interaction with LPS the cells produce peptide and 
lipid mediators such as interlukin-la, interlukin-lb tumor necrosis factor (TNF), 
interlukin-6, interlukin-8 and oxidative metabolites of fatty acids. The mediators 
produced and released by these cells are responsible for the endotoxic effects such as 
Fever leukemia, hypotension, and septic shock. LPS is composed of two chemically 
dissimilar structure regions: the hydrophilic repeating polysaccharide of the core and O-
antigen structure and a hydrophobic domain known as lipid A. the O-specific chain 
contain repeating oligosaccharides o up to five sugar residues. Considerable structural 
diversity is noted among O-specific chain structure from different gram-negative 
bacteria, and in general the major anti-LPS immune response is to O-antigen specific 
polysaccharide. Substantially more conservation of structure is noted within the core. 
Virtually all LPS-induced biologic response are lipid A dependent. The most 
compelling evidence supporting the concept that lipid A is the biologically active moiety 
of LPS derives from studies with synthetic lipid A. this product has full toxic activity. 
Thus the recognition of lipid A of LPS by cells must be initial step in LPS-induced 
response. The general chemical structure of lipid A from a diverse gram-negative bacteria 
is high conserved. The discovery of PS binding proteins was the single most important 
event to the major advances occurring since 1990in determining how LPS stimulate cells. 
A major function of LBP is to enable LPS binding to either membrane or soluble CD14. 
LPS appears to have two functional domains, one for LPS binding and another that foster 
LPS-CD 14 interactions. Support for multifunctional domain in LBP has derived from 
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analyses of structure-function relationship of BPI as well as from analyses of the 
properties of truncated forms of LBP. 
To explain how mCD 14 function as an LPS receptor, Ulevitch ,1995 have 
considered three models based on what is knowing about signaling through GPI-anchored 
protein in general. Model I the " single receptor" model, poses that signaling is initiated 
after of LPS to mCD 14; communicating with the cell interior is provided by a 
transmembrane protein recognizing the GPI-anchor of mCD 14. In contrast Model II and 
III suggested that the LPS receptor is multimeric , where mCD 14 is the principal ligand 
binding subunit and additional transmembrane protein transduces signals. Model II 
suggest that after binding LPS, mCD 14 undergoes a conformational change and then 
interacts with transmembrane protein; Model III propose that mCD 14 enable LPS 
binding to a transmembrane protein. 
III. Cytokines 
Cytokines, which are a divers and increasingly large group of biologically active 
glycoproteins, can mediate autocrine or paracrine interactions in many tissues. They were 
initially described as immunological factors important in the inflammatory response and 
as much may be implicated in the pathogenesis of many diseases. Over the last decade a 
large body of evidence has accumulated to implicate Cytokines in the control of bone cell 
activity (Gowen M, 1986) 
1. Local production and regulaion of Cytokines in bone 
In order to qualify, as a potential regulator of bone remodeling any Cytokines must be 
produced locally. Such local production may be achieved by non-skeletal cell 
14 
(haemopoietic or immunological) within the bone microenvironment but evidence is 
accumulating to show that osteoblast (and possibly osteoclast) mat also produced these 
factors and thus may capable of regulation their own function. This may have additional 
importance in osteoclastogenesis as the secretion of growth factors into the bone matrix 
may provide control mechanisms for future bone remodeling events. The available 
evidence suggest that osteoblast are capable of secreting most of the osteotropic 
Cytokines in vitro. However, it is possible that species differences exit and that synthesis 
of Cytokines assume greater or lesser importance depending on the local cellular events 
such as osteoclast activation or inhibition of bone formation or the stage of development 
Of the skeleton (Mac Donald and Gowen, 1992). 
It is clear that many Cytokines fulfil at least two of the criteria required for a role in 
controlling the cellular events of the bone remodeling cycle( osteotropic effects and local 
production). However, the effect of cytokines on the bone cells must also subjected to 
Control in order to render bone remodeling sensitive to local and generalized factors that 
influence bone remodeling. There are a number of possible ways of influencing 
Cytokines actions, many of which have not yet been examined in the contact of skeletal 
cell metabolism. 
The bone microenvironment contain cell capable of producing a number of different 
Cytokines and it is possible that the action of one Cytokines may be mediated or 
enhanced by local production of another Cytokines with similar effects. However, to date 
there is little evidence for such effect on bone. IL-1 has synergistic effects on hon 
Resorption in vitro with TNF-a and IL-6 (Black KS, Mundy, 1989). 
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The role of local prostaglandin synthesis in the medication of cytokines stimulated bone 
resorption has not been clearly defined. It is known that cytokines can stimulate 
prostaglandin synthesis by osteoblasts and that prostaglandin can stimulate 
multinucleated cell formation and bone resorption. However, different groups have 
shown either partial inhibition or no effect of indomethacin on cytokines-stimulated bone 
resorption. It seems likely that these differences are related to models of bone resorption 
employed or the preparation of cytokines used in the experiments. 
A. Interleukin-1 (IL-1) and its receptor 
It is well known that monocyte and tissue macrophages play important role in the 
regulation of various cellular function by virtue of synthesizing unique cytokines. Two 
major monocyte macrophage-derived cytokines tumor necrosis factor and interleukin 1 
(IL-1) have been well characterize. (Junming L, 1987). Interluekin-1 is a key mediator 
and modulator of a wide array of physiological response important for survival. It is 
secreted by a variety of cell type, including immune cells, Gila, and neurons. It is a very 
potent biological molecules, action both at the periphery as well as within the central 
nervous system. The production and release of IL-1 is tightly regulated by far more 
complex process than previously though. Two fundamental properties of IL-1 as being 
both as a mediator of disease as well as a host defense. However in either situation, over 
or continued production of IL-1 leads to debilitation of normal host function; therefore, 
reduction of IL-1 synthesis or its effects becomes a target of therapy in many disease. 
Three member of the IL-1 family have been cloned. All bind both types of receptor but 
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only two IL-1 a and IL-1 b are agonistic. The third is the interluekin-1 receptor antagonist 
protein . IL-1 a and IL-1 b are produced mainly in response to many stimuli including 
bacterial lipossacharide (LPS) , other microbial products, cytokines (TNF, interferon 
gamma, GM-CSF, IL-2), T cell/antigen cell interactions and immune complexes. 
IL-1 causes leukocyte accumulation by inducing adhesion receptors on vascular 
endothelium and stimulating chemokine production. It also causes the production other 
cytokines, prostanoids and nitric oxide( Stylianou E, 1998). 
There are two IL-1 receptors( IL-1 R), the type 1 receptor (IL-1 RIO transduces a signal, 
whereas the type II receptor (IL-1 RII) binds IL-1 but does not transduces a signal. In fact, 
IL-lRII acts as a sink for IL-lb and has been termed a "decoy" receptor, which somewhat 
unique to cytokines biology. When IL-1 binds to IL-lRI, a complex is formed that that 
then binds to the IL-IR accessory protein (IL-lR-AcP), resulting in high affinity binding. 
It is likely that the heterodimerization of the cytosolic domains ofIL-lRI and IL-lR-AcP 
triggers IL-1 signal transudation. The exrtracellular or "soluble" proteins of the IL-1 RI 
and IL-1 RII circulate in health and disease functioning as natural " buffers" binding IL-
1 a, IL-1 b, or IL-1 Ra. In addition, several cytokines exert a negative influence on both 
production and activity of IL-1 ( Dinarello CA, 1996). 
B. Tumor necrosis factor (TNF) and its receptor 
TNF is a cytokine, which is mainly produced by activated macrophages, although 
several other cell types can, produce small amount. The original interest in TNF is its 
antitumoral activity. The trimeric TNF exert its effort by binding to and cluttering 
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specific high-affinity receptors which are present on he plasma membrane of almost all 
cell lines, the number varying between 100 to 100,000 (Beyaert Rand Fiers W, 1994). 
Two distinct forms ofTNF have been identified TNF-a and TNF-p,.TNF-a and TNF-
Pshare identical biologic activities as they bind to the same receptors. The biologic 
manifestation includes among others, septic shock, acute phase response, bone resorption, 
production of pyrogens etc (Ksontini 1998, Beyaert 1994 ). TNF-a is a potent cytokine 
produce mainly by activated macrophages/monocytes, but it is also synthesize by the 
other cells TNF-a is also though to play a pivotal part in inflammatory process, since it is 
the first cytokine to be detected in the serum in endotoxemia and bacteremia. TNF-Pthat 
is primary a product of activated T lymphocytes, has also been called lymphotoxin. 
So far two types of receptor with a molecular mass of 55kDa (p55) or type I receptor 
and 75kDa ( P75) or type II receptor, have been identified for TNF signaling pathways. 
The receptor types consist of an extracellular domain, which binds TNF and is 28% 
homologous, a transmembrane region, and an intracellular part, which is totally different 
and does not contain any recognizable structure, which can be associated with a particular 
function. The P75 receptor has a 10 fold higher affinity for TNF molecules but ahs not 
been shown to trigger any biologic activity aside for T cell proliferation and apoptosis. In 
contrast the P55 receptor has been shown to be responsible for all TNF activity and also it 
has a high affinity to mediates the TNF activity (Beyaert 1994, Tartaglia 1991). 
Several investigators have shown that TNF is one of the effective mediators to stimulate 
the formation of osteoclast-like cells in human marrow cultures and bone resorption and 
modulation of osteoclastogenesis. 
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Amar et al. 1996, also, on the series of wound healing studies showed that the extent 
of LPS-induced skin necrosis was reduced in TNF receptor deficient mice. These studies 
suggest that TNF should be considered the principal mediator of LPS-induced toxicity. 
C. Interlukin-11 
a. Structure 
IL-11 was identified in 1990 as a molecule other than IL-6 in supematants from 
Transformed stromal cells that stimulated the proliferation of" IL-6 dependent" 
Plasmacytoma cells (Paul 1990). The IL-11 cDNA encodes a 199 aminoacids precursor 
with a 21-residue hydrophilic signal sequence. The gene for human IL-11 is 7kb in size, 
contains five exons and four introns. Two RNA transcripts of 1.5 and 2.5 kb are 
expressed from the IL-11 gene owing to the use of two polydenylation sites. There is 
little information about the three dimensional structure of IL-11 protein. However, a 
structural motif with four a-helical bundles has been proposed based on the high helicity 
of the molecules(Elias 1994 ). 
b. synthesis 
IL-11 transcripts can be detected in vitro in a variety of appropriately stimulated 
stromal cells including fibroblast, osteosarcoma, epithelial cell, chondrocytes, 
synoviocyte, osteoblast and glibolastoma cells. The stimuli that induced IL-11 vary from 
tissue to tissue. They induced TGF-b l _3 , IL-1, TNF, parathyroid hormone, and 
parathyroid hormone-related protein, calcium ionophores, phorbol ester and a variety of 
viruses including respiratory syncytial virus (RVS) (Elias 1994). Histamine and 
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eosinophil major basic protein (MPB) augment cytokines-induced IL-11 production, 
while heparin, steroids and interferon-a inhibit IL-11 elaboration. 
c. Specific receptor 
The IL-11 specific receptor is a multicomponent complex. It contains an IL-11 
specific a-chain and a 130kDa-signaltransducing subunit (gp 130), which is also in the 
receptor of the other IL-6 type cytokines (IL-6, leukemia inhibitory factor, etc). The 
human IL-11 receptor a-chain has been cloned and mapped to the chromosome 9 
(Nandurkar 1996, Cherel 1996). The mechanisms of IL-11 mediated transduction are not 
yet completely delineated. Current view holds that IL-11 binding leads to the formation 
Of gp 130 homodimers that, in tum active several potential signal transduction pathways. 
d. biologic function 
IL-11 is a pleotropic molecule. It is an important regulator of hematopoiesis where it 
stimulates megacaryocytopoieses in vivo and in vitro, stimulates erythropoiesis and 
regulates macrophage proliferation and differentiation. It also 
stimulates the proliferation of a variety of plasmacytoma cell lines, stimulate B cell 
immunoglobulin production, inhibits adipogenesis, regulate neuronal differentiation, 
stimulate the production of tissue inhibit of metaloproteinases-1 and activate osteocalsts. 
IL-11 is also a potent in vitro stimulator of he hepatocyte production of a variety of 
antiproteases and other serum protein referred to as the acute phase response proteins. 
The vivo importance of these stimulation is however open to question (Gabay 1996). 
One of he intriguing effects of IL-11 is its ability to protect in the setting of mucosa! 
injury. These effects are most prominent in the GI tract where IL-11 protects small 
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intestinal cells after combined radiation therapy and chemotherapy, reduce experimental 
mucositis and ameliorates injury in models of inflammatory bowel disease ( Keith 1994 ). 
3. Prostaglandins (PGs) 
A. Synthesis and source of PGs 
There is considerable evidence that prostaglandin are involved as mediators of 
inflammation (Vane 1974). The 20-carbon unsaturated (essential) fatty acids having 3, 4 
or 5, all-cis double bonds ( eicosatrienoic, eicosatetraenoic and eicosapentaenoic acids ) 
are the most usual substance for enzyme, the position of the double bond being C-8, 11, 
14. The substrate acids can derive from cellular phospholipids, cholesterol esters, and 
plasma triglycerides or non-esterified fatty acids. The initial step in synthesis of 
prostaglandin involves cleavage of arachidonic acid or dihomo- gamma- linolenic acid 
from esterification sites in membrane phospholipids and to a lesser degree in triglycerids 
and cholesterol ester. Esterified arachidonic acid cannot be converted to prostaglandin 
until hydrolyzed its unbound from. One enzyme which is clearly important in some cells 
in this action is phospholipase A2 which cleavage arachidonic acid from 
phosphatidylcholine and phosphatidylinostiol. The free arachidonic acid must then reach 
the microsome, which is he major site of prostaglandin synthetase adds molecular oxygen 
to the fatty acid and cyclize it the cyclic endoperoxide (Stewart A , 1981 ). 
The morphonuclear (PMN) leukocyte has been suggested as a possible source of 
inflammatory prostaglandin on the basis of observed in vivo prostaglandin E production 
by rabbit PMN leukocyte (Zurier Sayadof, 1975). The macrophages another prominent 
infiltration haematogenous cell, is known to contain a high proportion of arachidonic acid 
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in membrane phospholipase A1 and A2 that can be activated by phagocytosis and to 
undergo lipid peroxidation following phagocytosis (Stossel, Mason 1974). 
B. Bone resorption induced by prostaglandin 
PGE2 production by stromal cells can be regulated by many cytokines, such as IL-1, 
IL-6, basic fibroblast growth factor and tumor growth factor beta family. 2 metabolic 
processes; the release of arachidonic acid from phospholipids and its conversion to 
prostanoid regulate PGE2 synthesis. Cox is well known to be rate-limiting enzyme for 
conversion. The Cox-1 gene is constitutively expressed in many tissue. On the contrary 
the Cox-2 gene is undetectable under physiological condition, but is induced by 
cytokines. Cox-2 dependent PGE2 synthesis by stromal cell is though to play an 
important role in inflammatory bone resorption (Tai, Miyaura 1997). In the study by 
Ueda et al. They found that there was a good correlation between the number of 
osteoclast formed in bone marrow culture and the amount of PGE2 released into culture 
media. Furthermore, they detected increased level of Cox-2 when mouse bone marrow 
cells were stimulated with LPS. These finding suggest that the induction of Cox-2 by 
LPS result in increased PGE2 synthesis and osteoclast formation in cultures (Ueda, 1998). 
C. Inhibition of prostaglandin production by indomethacin 
28 year ago, Vane proposed that the mechanism of action of the aspirin-like drugs) non-
steroid anti-inflammatory drugs; NSAIDs) was through the inhibition of the 
prostaglandin biosynthesis and, there is now a general acceptance of he theory. The 
inhibition by aspirin is due to the irreversible acetylation of the cyclooxygenase (COX) 
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site of prostaglandin endoperoxide synthase, leaving the peroxidase activity of the 
enzyme unaffected. In contrast to this unique irreversible action of aspirin, other NSAIDs 
such as ibuprofen or indomethacin produce reversible or irreversible COX inhibition by 
competing with the substrate, arachidonic acids, for active site of the enzyme ( Vane JR 
1971). The inhibition of prostaglandin synthesis by NSAIDs has been demonstrated in a 
wide variety of systems, ranging from microsomal enzyme preparations, cells and tissue 
to whole animals and man . we know that there are at least two isoenzymes, named 
COXl or PGH synthase-1 and COX-2 or PGH synthase -2 (Xie W , Robertson DL, 
1994). 
Individuals NSAIDs show different potencies against COX-1 compared with COX-2 
and this satisfactory explains the variations in the side effects of NSAIDs at their anti-
inflammatory doses. Drug with high potency against COX-2 and therefore a lower 
COX-2 /COX-1 activity ratio, have anti-inflammatory activity with fewer side effects in 
stomach and kidney. Garcia Rodriguez and Jick, have published a comparison of 
epidemiological data of the side effects of NSAIDs. Piroxicam and indomethacin are 
amongst those with the highest gastrointestinal toxicity. These drugs have a much higher 
potency against COX-1 than COX-2 (Vane JR and Botting RM, 1995). Thus when 
epidemiological result are compared with COX-2/COX-1 ratio, there is a parallel 
Relationship between gastrointestinal side effects and cOX-2/COX-1 ratios. 
D. Assessment of selectivity of the indomethacin by using different models 
A number of methods have been described for determining the ED so values for 
NSAIDs against COX-2 and COX-1, leading to values for the COX-2/COX-1 ratio. 
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Table 1 shows values for indomethacin, which vary between 0.07 and 60 (Grossman CJ, 
Wiseman J, 1995). Clearly cultures of cells from animal give relatively high values 
whereas microsomal human enzyme preparation give a different set. Some of the reasons 
of variation have been identified. For example, laneuville et al. Added drugs and 
substrate to the human microsomal enzyme at the same time but not noted that several 
NSAIDs, including indomethacin, take 10-20 min to produce a full enzyme inhibition. 
when the drug was incubated for 20 min with enzyme before adding substrate, 
indomethacin was far more potent (especially on COX-2) and the ratio was reduced to 
3.5. Other conditions that will lead to variation in results are the absence of protein in he 
medium and the several hours taken to induce COX-2 in cells. 
Despite these methodological variations the ratio still fall into three broad groups; 
high ratios for indomethacin, naproxen and piroxicam, approximately equi-activity on the 
two enzymes for diclofenac and ibuprofen and selectivity for COX-2 for nimesulide, 
meloxicam, etodolac, MK-966 and celecoib. Thus the most results published so far 
support the hypothesis that the unwanted side effects of NSAIDs are due to their ability 
to inhibit COX-1 whilst their anti-inflammatory (therapeutics effects) are due to 
inhibition of COX-2. 
IV. Studies in inhibitory effects of Anti IL-11 antibody on 
osteoclastogenesis 
The result of study by Girasole and Passeri, on 1994 demonstrated that IL-11 is 
indeed a potent inducer of osteoclast development as evidence by its ability to induced 
osteoclastogenesis and bone resorption at concentration as low as 50pM. in addition 
IL-11 production by bone marrow cells can be stimulated l,25(OH)2D3 and PTH, and 
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that neutralization of IL-11 in bone marrow cell cultures suppress the ability of either the 
hormones to induce to induce osteoclast development. We also found that as is the case 
for the osteoclastogenic effects of l,25(0H)2D3 and IL-I, the ability ofIL-11 to stimulate 
osteoclast formation is likely dependent on prostaglandin. 
Also they found that based on the amount of IL-11 detected in culture supematants of 
the experiment one should predict that about 1-5 ug/ml of anti IL-11 antibody would 
indeed be required to neutralized the activity of IL-11 presented in theses l ,25(0H)2D3 
treated marrow cell cultures. They also found that the anti IL-11 antibody partially 
inhibited osteoclast development induced by either hrIL-1 b or hrTNF-a, indicating the 
critical role of IL-11 in the osteoclastogenetic effect of both systemic hormones and 
locally produced cytokines. In contrast to the finding for a partially dependency of the IL-
I or TNF-induced osteoclast development on IL-11, the IL-I I induced osteoclast 
development was not affected by the IL- I receptor antagonist or by a neutralizing 
antibody against both TNF-a and TNF-b. therefore the osteoclastogentic effect of IL-11 
do not seem to require IL- I or TNF. 
In a dose dependent fashion , by the cyclooxygenase inhibitor indomethacin, they also 
found that prostaglandins are likely involved in the stimulatory effects of IL-11 on 
osteoclasto genesis. 
V. Studies in prostaglandin induced bone resorption in 
transgenetic mice 
Takahashi, 1994 examined the effect of IL- I b on the osteoclast formation and PGE2 
production in the mouse bone marrow cell cultures of knockout mice. As we know IL-I b 
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caused a remarkable increased in the number of osteoclast in a dose dependent fashion, 
which was accompanied by PGE2 production in the culture. they test the hypothesis of 
the relationship between PGE2 production and osteoclast formation in IL-1 b treatment 
They concluded that PGE2 production declined with increasing doses of indomethacin, in 
proportion to that , osteoclast formation is also declined. They also found that the 
stimulatory effect of IL-1 b on the osteoclast formation was blocked by indomethacin 
completely while the effect of PGE2 exogenously added to the culture was not blocked 
indomethacin at all. Concomitant addition of IL-1 b caused an additional increased in the 
osteoclast formation, and only the additional increased was blocked by indomethacin 
(Takahiro S, Ikuo M, 1997). 
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Materials and Method 
I. Experimental design 
1. preparation of agents 
Lipoppolysaccharide (LPS) from Escherichia coli serotype 055:B5 was purchased 
from sigma# L2880, for LPS 500 solution, 25 mg of LPS was dissolved in 5 ml of 
Phosphate Buffered Saline (PBS) which was supplied from GibcoBRL #21600-051 and 
the, lgr/2lit prepared stock solution, 500ug/100 ul, total of 4ml in 13 vials), the solution 
is sonicated for 5-10 seconds with sonicator, then it was aliquoted (0.3 ml/ vial/ 3 mice) 
and stored at -80 ° C, for LPS 100 solution (1 mg/ml), 1.0 ml of LPS 500 solution was 
diluted by the 4.0 ml of PBS stock solqtion and then it could be sonicated, aliquoted and 
stored as the LPS 500 solution. 
Anti-IL-11 monoclonal antibody (anti-IL-11 mAb) 1 lh3/19.6.l., (murine IgGl) a 
gift of Genetics Institute, Inc. (Cambridge, MA), was prepared freshly at 9.3 mg/ml in 
PBS before each injection according to Genetic Institute recommendations. Polyethylene 
glycol 8000 (PEG Av. Mol Wt 8,000) 40% (w/w) in water was purchased from sigma# 
P 1458, for preparation 20 ml of 1 % PEG, 500 ul of the polyethylene glycol 8000 (40%) 
was diluted by 19.5 ml of sterile water and stored at 4° C for 5 days ( pH 4.5-5). 
Indomethacine, (powder), ([1-[p-Chlorobenzoyl]-5-methoxy-2- methllindole-3-
acetic acid; C 19 H16CINO4; FW 357.8) was supplied from sigma# P1458, for 
preparation of 10% Indomethacine stock solution (10 mg/ml), 20 mg of the powder was 
diluted by 2.0 mll 00 % ethanol and stored at 4° C for 5 days at the injection time 1 % 
Indomethacine. 
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Working solution (1 mg/ml) was prepared by the following procedures; 100 ul of 
Indomethacine stock solution was diluted by 900ul of 1 % PGE within .a syringes system 
which was connected through a modifier, then the solution was pushed back and forth 
between two syringes until a uniform creamy appearance of the emulsion was observed; 
then the emulsion was aliquoted and stored at 4° C for 5 days. before each injection it was 
mixed well by shaking . 
Solution control of 1 % PEG and 100% Ethanol was prepared by the dilution of 100 ul of 
100% Ethanol by 900 ul of 1 % of PGE. Ketamine-Xylazine solution was prepared by the 
dilution of 1.0 ml Ketamine(l00 mg/ ml), Ketamine HCL Injection(Ketaset, FortDodge, 
IA), USP, 10 mg/ml and 1.0 ml ofXylazine(Rompum, Columbus OH), (20 mg/ml), 20 
ml/vial, with 6.0 ml of PBS stock solution . 
2. mice 
Three strains of mice were used in this study: transgenic mice with a targeted deletion 
of IL-1 receptor type I (IL-lRI- 1-), and both TNF receptor p55 and IL-1 receptor type I 
double knock-outs (TNFRpss- 1--IL-1Rr 1) were generously provided by Dr. J. Peschon 
(Immunex Corp., Seattle, Wash). Genetically matched wild-type C57BL/6 x129 hybrids 
were purchased from Jackson Laboratory (Bar Harbor, Maine). Mice were between 8 and 
12 weeks of age during the study. Regular mouse chow and water were provided 
ad libitum. The genotypes of mutant mice were routinely confirmed by PCR of extracted 
DNA. Each strain of mice was randomly assigned into a low dose ofLPS group (100 
ug/mouse) or high dose of LPS group (500 ug/mouse). Each group included 4 different 
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arms with 7 mice in each group. All procedures involving animals were approved by the 
Institutional Animal Care and Use Committee at Boston University School of Medicine. 
1) LPS challenge followed by anti-IL-11 mAb (LPS+anti-IL-11). 
2) LPS challenge followed by indomethacin ( LPS+Indo) ,was received both 
Lipopolysacharide and Indomethacine. 
3) LPS challenge followed by PBS (LPS+PBS) which was received Lipopolysacharide 
(LPS) from E.coli. 
4) saline challenge followed by PBS (saline+PBS) severed as control, which was 
received Phosphate Buffered Saline (PBS). 
3. calvarial injection 
All animals were anesthetized intramuscularly with a Ketamine-Xylazine stock 
solution 0.15 ml per mouse, about 5 ul of anesthetic solution per gm of body weight. The 
heads of the anesthetized mice were shaved and received subperiostal injection. Injection 
were administered using a 30.5 gauge needle sigma #14-826 Fat a point of the middle of 
the skull located between the ears and eyes( typically 0.2-0.3 cm from the frontal suture or 
just between the frontal and lambdoiod sutures). In the initial time course experiment one-
dose of LPS (100 or 500 µg/mouse) or saline, each in a 100 µl volume, was injected . 
subcutaneously, then immediately followed by a same-site injection of 50 µI/mouse of anti-
IL-11 mAb (465 µg/mouse), indomethacin (50 µg/mouse) or PBS. For subsequent 
treatments, all mice were anesthetized via inhaled isoflurane prior to their injections. 
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Thereafter, anti-IL-11 mAb (465 µg/mouse) or PBS, each in a volume of 50 
µI/mouse, was administrated subcutaneously every 4 hours for a total of 4 injections 
(total dose of 1.86 mg anti-IL-11/mouse). Indomethacin (50 µg/mouse) or PBS was 
injected in a 50 µl volume every 8 hours, for a total of 9 injections (total dose of 450 µg 
indomethacin/mouse ). Mice were sacrificed in a CO2 chamber 5 days after the first 
injection. 
II. Mice Scarification and Specimens Process 
1. preparation of fixing solution 
50 gram of paraformaldehyde (powder) sigma# P 6148 was diluted by 500 ml of 
PBS on a heated stirring plate at a temperature about 65 °C, then a few drop of 10 N 
NaOH was added to solution and wait until it become clear, solution was back to the 
room temperature and the pH was adjusted by adding 12 N HCL around 7.2-7.3, in 
order to prepare 10% Paraformaldehyde stock solution. Then 50 ml, 100 ml, 150 ml, 
Glycerol lL sigma# G 7893 was diluted by 950 ml of PBS (pH 7.2-7.4) in order to 
preparing of the 5%, 10%, 15% PBS-Glycerol washing solution respectively. 
Thereafter 300 g Sucrose sigma #55016was diluted by 1000 ml PBS (pH 7.2) in order 
to PBS- 30% Sucrose solution. 
2. Tissue preparation 
The entire calvarial bone together with the overlying skin tissue was dissected and 
fixed in freshly prepared paraformaldehyde (4% in PBS, pH 7.2) for 6 hat 4°C. The 
specimen was then washed with 5, 10, and 15% glycerol in PBS each 
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for 15 min, and decalcified in Immunocal solution (Decal Corporation, congress NY) 
for 3 days at 4°C with gentle stirring. After two washes with Immunocal Neutralizer 
Solution (Decal Corporation, congers, NY) for 20 min at 4 °C, the anterior half of the 
frontal bone and the posterior half of the occipital bone were trimmed off. The 
remaining calvarial bone, with its overlying skin tissue, was immersed in 30% sucrose 
in PBS overnight, and then transferred into -80°C pre-chilled 2-methyl-butane (Sigma) 
and stored at -80°C until embedding. Specimen were trimmed to a size that allowed it 
to fit in the Histopreparation tissue capsule (38mm x 8mm) Fisherbrand # 15-182-218 
by specially retaining scalp. 
III. Histochemical staining 
After embedding the specimens in Frozen Tissue Media, Fisher# SH 75-
125D, the blocks should be keep in-20°C for 2 hours before sectioning. The 
Calvarial bones were sectioned in half through their sagittal suture and both halves 
were prepared for frozen sectioning. Transverse 5 um-serial sections were made by 
cryostat sectioning. For each specimen, 25 slides were obtained and every fifth 
slides was stained for Tartarate Resistant Acid Phosphate, TRAP, a known marker 
for osteoclasts. The slides were incubated for 5 minutes in the TRAP solution at 
37°C in the dark, washed for 30 minutes and then counterstained with hematoxylin 
solution, Mayer's sigma# MHS-1. The TRAP solution was prepared as following: 
210 mg of fast red-violet LB Diazonium salt sigma F-3381 was dissolve in a mixture 
of 0.2 M acetate buffer (pH 5.0) and 10% MgCh (8 drops of 50 ul) up to 150 ml, 
1.455 g of tartaric acid sigma# T- 6251, MW 194 was added to the solution then 
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24mg of naphthol AS-B 1 phosphate sigma# N-2250 was dissolve in 1.5 ml of N-
dimethylformamide sigma# D4254and added to the fast red violet solution. The 
mixture was filtered through a 0.22 um pore size filter. 
IV. Bone histomorphometery of calvarial suture surface 
1. Criteria of measurement 
For each specimen, 4 slides containing two sections were analyzed. The 
measurement was performed at magnification of x 100 and x 400, which were 
analyzed by computer-assisted image analysis (Image Pro plus image software 4.0, 
Media Cybernetics, MD), in the segment of bone between the half of the frontal and 
the interpatietal bone (sagittal, coronal and lambdoid sutures). Only the data from 
frontal suture and lambdoid sutures of one tissue section of each slide, which kept 
intimate tissue structure together with the most number of osteoclast, were chosen 
into statistic analysis. Total area of the coronal (frontal) suture and lambdoid suture 
were measured in each tissue section. Measurements consist of: bone surface (BS), 
the length of two periosteal surfaces in each suture, was identified at 1 00x 
magnification, the number of the osteoclast: number of the osteoclasts per square 
millimeter (N.Oc/mm 2)of the bone surface, identified at 400x or l00x 
magnification,osteoclast surface active resorption surface (Oc.S/BS), the 
percentage off bone surface covered by osteoclasts. This was calculated as sum of 
the length of osteoclast within the Howship's lacuna divided by the total bone 
surface, identified at 400x or 1 00x magnification, individual osteoclast activity 
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(ES/N. Oc) which was calculated as the ratio between active eroded surface and 
osteoclast number(resorptive activity of osteoclast). 
2. Criteria for recognition of osteoclast 
On histological sections, osteoclast were identified at 400x magnification as large 
multinucleated and TRAP positive stained cells that lie in apposition to a bone surface 
under going lacunar resorption(resorption in Howship lacunae). All slides were coded by 
one person and analyzed by another person. The results were verified by a second 
examiner. Inter-examiner and intra-examiner variation was generally less than 10%. 
V. Statistics 
Results are displayed as mean± standard deviation (SD). There were 7 mice in each 
group (n = 7). ANOVA was used to analyze differences among groups; in addition, 
Fisher's one-way analysis of variance and an unpaired 2-tailed Student's t test were 
performed to compare results between treatment groups, and statistical significance was 
assumed for probability values~ 0.05. 
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Result 
A total of 21 mice, first generation, PCR confirmed genotypely, from three different 
strains were used in this study: Transgenic mice with target deletion of IL-1 receptor type . 
I (IL-lR r'-) or both TNF receptor p55 and IL-1 receptor, with matched wild type. They 
were between 8 to 12 weeks and randomly assigned into a low dose group 
(l00ugLPS/mouse) or high dose group (S00ugLPS/mouse). In the initial time course 
experiment which was submitted to the day zero a single dose of LPS (S00µg/1 00µg) or 
saline, 1 00ul in volume, was injected subcutaneously which was immediately followed 
by a total of 4 injections of anti-IL-11 mAb (50 ul/mouse per injection) or PBS every 4 
hours and a total of 9 injections of indomethacine or PBS (50 ul/mouse per injection) 
every 8 hours. On the day 5th all mice were scarified. 
Histomorphometric analysis revealed that bone resorption evidenced by stained 
osteoclast in Howships lacunae. All of the osteoclasts counted in this study were mature 
osteoclasts, and had to have met the following criteria: large multinucleated cells, TRAP-
positive staining, lying in apposition to a bone surface, and undergoing lacuna resorption 
(resorption in Howship lacunae). Bone resorption seemed to involved predominately the 
suture of the calvarium bone, as osteoclasts populations were observed concentration in 
and around suture area. Surprisingly very few to no osteoclast was observed on the 
periosteal bone surface directly underlying the scalp. Only sutural bone resorption and 
multinucleated TRAP positive cells within this area were quantified. The area of bone 
resorption and individual osteoclast activity was assessed on three calvarial bone suture 
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surface by usmg a computer assisted Image Analysis set up. We calculate three 
parameters on suture area: 1) the percentage of bone surface covered by osteoclasts, 
which represents the extent of the bone resorption on the suture area. 2) Osteoclast 
number (ON, e.g. osteoclast index), which reflects changes affecting osteoclast 
formation; 3) individual osteoclast activity (IOA, µm/cell), which is the length of lacuna 
resorption per osteoclast. 
The percentage of bone surface covered by osteoclasts in low dose 
experimen t(l 00ugLPS/m o use). 
In our low dose study group the histologic picture was not as dramatic as in the high 
dose group which received a 500µg LPS injection. Fewer osteoclasts and less area of 
bone resorption were counted. However following penetration of calvarium by 1 00µg 
LPS the osteoclast index and osteoclast surface parameter were still significantly greater 
in LPS group compare to the base line in all three strains of mice (all p<0.01). The 
percentage of bone surface covered by osteoclasts reflects the extent of the bone 
resorption on the suture bone surfaces. As seen in Figure 1, the low dose of LPS (100 
µg/mouse) induced an approximately 3.7-fold increase in this parameter in all three 
strains of mice (LPS+PBS vs. saline+PBS: 15.18% ± 0.45% vs. 4.05% ± 0.22% in wild-
type; 15.26% ± 0.30% vs. 3.95% ± 0.25% in IL-lRi- 1·; 14.80% ± 0.71 % vs. 3.96% ± 
0.28% in TNFRp55·1--IL-1Rr 1} We also compare the effect of IL-11 in low dose 
experiment. Table 2 expressed the data regarding ability of IL-11 neutralizing antibody to 
inhibit osteoclast formation. Anti-IL-11 reduced osteoclast coverage by approximately 
37% in wild type mice and 40% in mutant type (all p<0.01), and indomethacin reduced 
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the percentage of bone surface covered by osteoclasts by approximately 46% in wild type 
mice and approximately 50% in knot out mice (allp < 0.001) in all three strains of mice. 
We also find that low dose of LPS challenge cause no difference in the osteoclast 
response between the transgenic and the wild which means that bone resorption activity 
of sutural area proceeded throughout a pathway independent of the IL-1 and TNF 
receptor signaling. 
The percentage of bone surface covered by osteoclasts in high dose 
experiment (500ugLPS/mouse). 
On this part of experiment quantitative analysis of osteoclast coverage at higher 
dose of LPS revealed a more complex picture than low dose experiment (Figure 2 and 3). 
Data of this experiment was shown on table 3. Wild type mice and mutant mice both had 
the same percentage of bone surface covered with osteoclast following injection vehicle 
(PBS+Saline) only. In our light micrographs observations (Figure 3) of mouse calveriae 
injected with 500 µg of LPS and treated with either PBS (Figure 3.1), anti-IL-11 mAb 
(Figure 3.2) or indomethacin (Figure 3.3) in wild-type mice. Fewer osteoclasts in 
resorption lacunae were observed for all of the mutant mice compare to their matched 
control, indicating that at least some of the osteoclast activity was dependent on IL-1 R (-/-) 
or TNF p55 (-/-)_ However, wild type mice exhibited a An approximately 8-fold increase in 
osteoclast coverage of bone surface mice by high-dose LPS challenge (Figure 2, 32.35% 
± 1.65% in LPS+PBS group vs. 4.05% ± 0.22% in saline+PBS group). This is in contrast 
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with about 5-fold increase observed with high-dose of LPS in either the IL-1 ru-1 ( 19 .18% 
± 0.96% in LPS+PBS group vs. 3.95% ±0.25% in saline+PBS group) or the TNFRp5S-1--
IL-1RI_1_ mice (18.93% ± 0.85% in LPS+PBS group vs. 3.95% ± 0.28% in saline+PBS 
group). In contrast, in wild type mice Anti-IL-11 inhibited osteoclast coverage by 
approximately 55% which arguing for a Significant contribution of IL-11 in the 
inflammatory response of these mice and 40% in mutant type (all p<0.001). It is well 
known that cyclooxygenase is a rate limiting enzyme For conversion of arachidonic acid 
to prostanoids. The data expressed on table 2,3 compare changes of osteoclast number in 
suture area of calvarium by targeted deletion of prostaglandin from calvarial suture 
environment. A significant inhibition of osteoclast coverage by 70% (p < 0.001) in wild-
type, and approximately 57% (p < 0.001) inhibition in IL-lRI_,_ and TNFRp55-1--IL-1RI_1_ 
mice were seen. Furthermore, quantitative histologic examination revealed that there 
were fewer osteoclasts and less bone surface in contact with osteoclast in 1 00µg 
LPS/mouse group compare to 500µg LPS/mouse group (compare table 2 & 3). 
Indomethacin showed a slightly higher activity than anti-IL-11 mAb in reducing LPS-
induced bone resorption in high-dose LPS-challenged mice (Figure 2), since the two 
treatments differed by a significant degree in wild-type (p = 0.05), IL-lRl _,_ (p < 0.05) 
and TNFRp55-'--IL-1Rl _1_ mice (p < 0.05). 
Osteoclast number in low dose experiment (l00ugLPS/mouse) 
on this part of experiment quantitative analysis of osteoclast index consistently 
represents the same patterns as the measurements of percentage of bone surface covered 
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by osteoclasts(figure 4). The lower dose of LPS similarly increased ON up to 3.7-fold (all 
p < 0.05) in all three strains of mice (3.95 ± 0.17 vs. 1.03 ± 0.05 in wild-type mice; 3.91 
± 0.15 vs. 1.04 ± 0.08 in IL-lRl-\ 3.74 ± 0.30 vs. 1.02 ± 0.06 in TNFRp55-1--IL-1Rr1} 
We also compare the effect of IL-11 in low dose experiment. Table 2 expressed the data 
regarding ability of IL-11 neutralizing antibody to inhibit osteoclast formation. Also the 
osteoclast index was reduced by about 38% with anti-IL-11 mAb (all p < 0.01), or by 
around 52% with indomethacin (all p <0.001) in all three strains of mice. As The data 
shown in table 2 PGs and IL-11 enhanced LPS mediated osteoclastogenesis in this set of 
experiment . 
Osteoclast number in high dose experiment (500ugLPS/mouse) 
At high-dose LPS (Figure 5), osteoclast index (ON) increase by 7.3-fold in wild-type 
mice (7.51 ± 0.47 vs. 1.03 ± 0.05 in wild type, osteoclasts/mm) and by 4.2-fold in two 
strains of knockout mice (4.41 ± 0.26 vs. 1.04 ± 0.08 in IL-lRl-/-; 4.26 ± 0.30 vs. 1.02 ± 
0.06 in TNFRp55-1--IL-1Rr 1} However, anti-IL-11 mAb caused a 52% inhibition of ON 
by in wild-type mice and 32% inhibition in knock-outs (all p < 0.01). Similarly, 
indomethacin inhibited high-dose LPS-induced .ON by 69% in wild-type and about 56% 
in IL-lRr'- and TNFRp55-1--IL-1Rr'- mice respectively (allp < 0.001). 
Resorptive activity of osteoclast ( Individual osteoclast activity) in low 
dose and high dose experiment 
Our findings in this part of experiment are not interesting as our result in 
osteoclast coverage and osteocalst number in two other sets of experiment. Individual 
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osteoclast activity (IOA,µm/osteoclast) was calculated as the ratio between active 
eroded surface and osteoclast number. The results of this part of experiment indicated 
that following the treatment of vehicle (PBS+Saline) and indomethacine (LPS+Indo) 
there was no difference between IL-IR (-/-) and IL-IR (-/-)/TNF p55 (-/-) and their 
receptive wild type mice Table 3. Wild type mice and mutant mice both had the same 
Individual osteoclast activity (IOA,µm/osteoclast). Which means that Prostaglandins, 
IL- I and TNF signaling did not affect the regulation of resorptive activity of single 
osteoclasts in LPS-induced bone resorption, since there no significant differences were 
found among the three strains of mice. However, IOA was greater in response to high-
dose LPS than to low-dose LPS in all three strains of mice (high-dose LPS+PBS vs. 
low-dose LPS+PBS group: 43.80 ± 1.98 vs. 36.90 ± 1.54 in wild-type; 44.77 ± 3.57 
vs. 35.68 ± 1.92 in IL-IRI ·1·; 42.50 ± 2.28 vs. 36.52 ± 2.21 in TNFRp55·1--IL-IRi- 1-
mice, all p < 0.05). Most striking finding was the high dose LPS mediated bone 
resorption by increasing the resorptive activity of single osteocalst throughout the IL-
I I signaling pathway. As the data shown in table 3 IOA was lower in high dose 
LPS+anti-IL-I I groups than high-dose LPS+PBS groups in three strains of mice 
LPS+anti-IL-11 vs. LPS+PBS: 36.50 ± l.I5 vs. 43.80 ± 1.98 in wild-type; 34.83 ± 
1.05 vs. 44.77 ± 3.57 in IL-I_,_, 36.98 ± 2.05 vs. 42.50 ± 2.28 in TNFRp55·1--IL-IRI _,_ 
mice, all p < 0.05). · 
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Discussion 
During the past few years it has been established that interleukin- I, interleukin-6, 
Interleukin- I I and tumor necrosis factor (TNF) can stimulate osteoclast development 
And thereby the process of bone resorption. Two types of high-affinity receptors, p55 and 
p75, have been identified for TNF molecules. Most but not all TNF activity has been 
shown to be mediated by the TNF p5 5 receptor (Peschon, j. 1998, Rothe, and j. 1993 ). 
IL-1 is a potent stimulator of osteoclastic bone resorption in vitro and cause 
hypercalcemia and increased osteoclastic resorption when infused into normal mice for 
72 hours (Boyce BF, Garrett IR, 1989). There are two forms of biologically active IL-1 
(a and P) and two homologous receptors for IL-1 (type I receptor and type II receptor) 
that can bind either form ofIL-1, although with different affinities (Arenda, W. P., M. 
Malyak, F. 1994). The type 1 receptor is capable of mediating a biological signal, while 
the type 2 receptor is thought to function as a decoy receptor .Prostaglandin of E series, 
primarily E2 and E1, have the greatest activity in bone. Following discovery of their 
potent ability to stimulate bone resorption in vitro, clinical investigation have placed 
prostaglandin at sites of localized bone resorption associated with pro- sites may be 
increased by cytokines such as interleukin- I but the mechanism by which inflammatory 
cytokines these studies have shown that prostaglandin production at such prostaglandin 
stimulate bone resorption are not yet known (Norrdin RW, Jee WS, 1990). 
IL-11 that produced by marrow stromal cell, induced the formation of osteoclasts 
exhibiting an unusually high degree of ploidy in cocultures of murine bone marrow and 
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calvaria cells. Osteoclast formed in the presence of IL-11 were capable of bone 
resorption, as evidenced by the formation of resorption pits. Further Girasole and Passeri 
demonstrated that , an antibody neutralizing IL-11 suppressed osteoclast development 
induced by either parathyroid hormone, IL-1 or TNF had no effect on IL-11 stimulated 
osteoclast formation. They also concluded that the effects of IL-11 on osteoclast 
development was blocked by indomethacin (Girasole G. Passeri G, 1994). 
Osteoclast formation is induced by at least three different mechanisms. The first 
mechanism involves the gp130 signal, an important pathway of osteoclast formation, 
which is activated by cytokines such as IL-11, IL-6, and leukemia inhibitory factor. The 
second mechanism is the parathyroid hormone-IL-1-prostaglandin-E axis, which is 
mediated by signaling involving cAMP. The third mechanism is la,25-dihydroxyvitamin 
D3-induced osteoclast formation, which is mediated by the vitamin D receptor but 
independent of cAMP (Suda, T.,1999, Yasuda, H., N. Shima, N. 1998). Complete 
inhibition of cytokine activity can be obtained when cytokine or cytokine receptors are 
genetically deleted from experimental animals, targeted deletions of IL-1 and TNF 
receptors have been invaluable tools in dissecting out the roles of these cytokines in 
disease processes, particularly in the inflammatory response to LPS (Glaccum, M. B. 
1997, Peschon, J. 1998). 
The role of local prostaglandin synthesis in the medication of cytokines stimulated 
bone Resorption has not been clearly defined. It is known that cytokines can stimulate 
Prostaglandin synthesis by osteoblasts and that prostaglandin can stimulate 
multinucleated cell formation and bone resorption. It has previously been reported that 
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PGE2 production declined with increasing doses of indomethacin , in proportion to that , 
osteoclast formation also declined (Takahiro S and Ikuo M, 1997). These findings are 
consistent with our result, which demonstrated a decrease of bone resorption in all three 
types of mice in indomethacin group compare to their wild type counterparts in high dose 
experiment (500µg LPS/mouse). however, when low dose of LPS (100 µg) were injected 
there was no difference in the osteoclast response between the transgenic and the wild 
type mice. Based on these findings it appears that at low doses, the osteolytic activity of 
Other agents may mediate cytokines, which are induced by LPS, a plausible mediator 
could be IL-11. as previously mentioned IL-11 might induce bone resorption and this 
bone resorption was unaffected by inhibitors to IL-1 and TNF signaling, in contrast, IL-1 
and TNF induced bone resorption was inhibited by 50% when IL-11 antagonist was 
administered. (Girasole 1994). To examine this hypothesis we set up another experiment 
based on the elimination of IL-11 in the bone microenvironment. The suture area of the 
LPS of E.Coli combined with Anti IL-11 antibody injected mouse calvarium. IL-
1 Rand double knockout mice lacking both TNF p55 and IL-1 type 1 receptor exhibited 
the same amount of bone resorption as their wild type counterpart experiment . 
Amar et al. 1999, demonstrated that the effect of LPS on osteoclastogenesis is, in part, 
mediated by TNF and IL-1 receptor exhibited less osteoclast activity when challenged 
with a high dose of LPS compared to wild-type mice. They also concluded that there 
were also significant differences between the mutant mice in modulation of 
osteoclastogenesis. IL-IR(-/-) mice had significantly less LPS mediated osteoclastic bone 
resorption than the TNF p55(-/-)/p75(-/-) group and .TNF p55(-/-) /IL-IR(-/-) mice. Based on 
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these finding they concluded that both TNF and IL-I activity are important for LPS 
mediated bone resorption. Our findings suggest that LPS-induced bone resorption is 
mediated at least in part by IL- I receptor signaling, but not at low LPS doses. 
Furthermore current in vivo study demonstrates that at low dose, LPS-induced bone 
resorption is influenced by IL- I I and PGs, while at high dose, it is mediated by IL-1 I, 
PGs, and IL- I receptor signaling; IL-11 and PGs increase LPS-induced bone 
resorption by pathways independent of IL-1 or TNF receptor signaling; Finally IL-11 
and PGs increase LPS-induced bone resorption by enhancing osteoclast formation. 
The result of study by Girasole et al.(1994) indicated that IL-I 1 is indeed a potent 
inducer of osteoclast development as evidence by its ability to induced osteoclastogenesis 
and bone resorption at concentration as low as 50pM, They also found that the anti IL-1 I 
antibody partially inhibited osteoclast development induced by either hrIL-1 b or hrTNF-
a, indicating the critical role of IL- I 1 in the osteoclastogenetic effect of both systemic 
hormones and locally produced cytokines. In our study, IL-I I was involved in high dose 
LPS-induced bone resorption through enhancing the resorptive activity of individual 
mature osteoclast. As IL- I I receptor transcripts were detected in mature osteoclasts, it 
indicates that mature bone resorbing cells are potential targets of IL-11 (Romas, E., 
1996). That IL-11 was involved in mediating the resorptive activity of individual 
osteoclasts only after high dose LPS challenge suggests that there might be a critical 
threshold of the sensitivity of osteoclast activity for IL-I I. 
Effects of IL-1 I on osteoclast formation were prevented by indomethacin in vitro 
(Hill, P. A., Tumber, S. 1998) indicated that, as with IL-1 and TNF (Lader, C. S., and A. 
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M. Flanagan. 1998) the stimulatory effects of IL-11 also involved products of arachidonic 
acid metabolism ( Hill, P. A., Tumber, S. 1998). Therefore, the stronger ability of 
indomethacin in reducing bone resorption and osteoclastogenesis may have resulted from 
inhibition of not only PGs but also other cytokines (such as IL-11 and IL-1) which can 
mediate their effects through PGs in vivo. Our data also indicate that PGs have a stronger 
activity than IL-11 in LPS-induced bone resorption and osteoclastogenesis in vivo. PGs 
have been previously found essential for osteoclast formation in vitro. Without PGs, 
osteoclast formation and bone resorption are virtually nonexistent in cell and bone organ 
culture systems (Collins, D. A. 1991, Hill, P. 1998). 
Osteoclastic properties of IL-11 are distinct from the properties of other cytokines 
known to affect osteoclast formation, besides IL-6. The effect of IL-1 or TNF on 
osteoclast development depends, in part, on IL-11 whereas the effect of IL-11 is 
independent of IL-1 or TNF, indicate that IL-11 must provide a more complete and 
hierarchically more central signals of IL-1 and TNF. Unlike IL-11, which is produced by 
mesenchymal-derived adherent cells, the primary cellular source of IL-1 and TNF in the 
marrow is most likely the monocyte/osteoblastic cell for osteoclast formation, it is likely 
that the IL-11 signals for osteoclast development is juxtacrine, as opposed to the IL-1 and 
TNF signals that may be paracrine (Girasole et al.1994). These findings are consistent 
with our result, which demonstrated an equal of bone resorption in all three types of 
mice in which we might suggest that IL-11 signaling in osteoclastogenesis is independent 
of IL-1 and TNF receptor signaling in LPS-induced inflammatory bone resorption. 
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Conclusions 
In the present report, an attempt have been made to elucidate the role of IL-11, PGs, 
IL-1 signaling and TNF signaling in LPS-induced bone resorption and determine the 
relative role of each of these factors in the overall process of bone resorption for high and 
low dose of LPS. To our knowledge, this is the first in vivo study addressing the pathway 
I 
connecting LPS with bone resorption. At low dose of LPS, osteoclastic bone resorption 
was caused primarily by enhanced osteoclastogenesis, and this effect was mediated only 
by IL-11 and PGs signaling. In contrast, at high dose, LPS-induced bone resorption and 
osteoclastogenesis appeared to be mediated by a combination of IL-11, PGs and IL-1 
receptor-based signaling. Indomethacin showed slightly stronger activity in reducing 
LPS-induced osteoclastogenesis and bone resorption than did anti-IL-11 mAb. 
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LEGENDS 
Figure 1. The percentage of bone surface covered by osteoclasts in mice challenged 
with low dose of LPS. All mice received one-time low dose of LPS (LPS 100, 100 
µg/mouse) or saline, which was followed by anti-IL-11 mAb (Anti-IL-11, 465 µg/mouse 
x 4 injections), indomethacin (Indo, 50 µg/mouse x 9 injections) or PBS injections. Mice 
were sacrificed on day 5. Bars represent means ± SD and n = 7 for each group. * *: p < 
0.01; ***: p < 0.001; vs. LPSl00+PBS group in wild-type mice. #: p < 0.01, vs. other 
three groups in the same strain of mice. 
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Figure 2. The percentage of bone surface covered by osteoclasts in the mice challenged 
with high dose of LPS (LPS500, 500 µg/mouse ). The treatments are identical as Figure 1. 
Bars represent means ± SD and n = 7 for each group. Anti-IL-11: anti-IL-11 mAb. Indo: 
indomethacin. @: p < 0.001, vs. all other groups in this figure. #: p < 0.01, vs. other 
three groups in the same strain of mice. *: p ::; 0.05, LPS500+anti-IL-11 group vs. 
LPS500+1ndo group within the same strain of mice. 
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Figure 3. Light micrographs of mouse calveriae injected with 500 µg of LPS and 
treated with either PBS (Figure 3.1), anti-IL-11 mAb (Figure 3.2) or indomethacin 
(Figure 3.3) in wild-type (Figure 3.A), IL-lR1- 1- (Figure 3.B) and TNFRp5S-1--IL-1Rl _1_ 
mice (Figure 3.C). Histological sections of the calvarial bone were stained for TRAP and 
counter-stained with hematoxylin. t: TRAP-positive (red-staining) multinucleated cells 
in Howship's lacunae. BM: bone marrow. Indo: indomethacin. Original magnification, 
x200. 
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Figure 4. The osteoclast number (ON) of the calvarial bone surface in the mice 
challenged with low dose LPS (LPS 100, 100 µg/mouse ). All mice received one-time 
dose of LPS or saline, which was followed by anti-IL-11 mAb (Anti-IL-11, 465 
µg/mouse x 4 injections), indomethacin (Indo, 50 µg/mouse x 9 injections) or PBS 
injections. Mice were sacrificed on day 5. Bars represent means± SD and n = 7 for each 
group. **: p < 0.01; ***: p < 0.001; vs. LPSl00+PBS group in wild type mice. #: p < 
0.01, vs. other three groups in the same strain of mice. 
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Figure 5. The osteoclast number (ON) of the calvarial bone surface in the mice 
challenged with high dose LPS (LPS500, 500 µg/mouse ). The treatments are identical as 
Figure 4. Bars represent means ± SD and n = 7 for each group. Anti-IL-11: anti-IL-11 
mAb. Indo: indomethacin. @: p < 0.01, vs. all other groups in this figure. #: p < 0.001, 
vs. other three groups within the same strain of mice. 
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Table 1. Inhibition of COX-1 and COX-2 by Indomethacin, determined by using animal and 
humam model 
COX-2 COX-1 COX-1 and 
Model ICso(uM) ICso(uM) COX-2 Reference 
Cultured 145 6.6 22 Meade et al. 1993 
animal cells 1.7 0.028 60 Mitchell et al. 1993 
0.006 0.0002 30 Engelhart et al. 1996 
0.009 0.0015 6 Klein et al. 1994 
0.97 7.5 1.3 Futaki et al. 1994 
Human >1000 13 >75 Laneuville et al. 1994 
enzyme 1.4 0.6 2.3 O'Neil et al . 1994 
preparation 0.9 0.1 9 Gierse et al.1995 
0.1 0.35 3.5 Churchill et al 1996 
0.36 0.7 0.15 Patrignani et al. 1994 
Human cells 0.002 0.017 0.07 Grossman et al. 1995 
1.7 0.13 12.5 Young et al. 1996 
Table 1 shows values for indomethacin, which vary between 0.07 and 60 (Grossman CJ, 
Wiseman J, 1995). 
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Table 2. incidence of osteoclast number and osteoclast surface in mice injected with 100 
ug ofLPS. 
1ehicle 
Wild type mice IL-IR IL-1R/TNFp55 
#OC % surface #OC % surface #OC % surface 
mice 
1.03 ± 0.05 4.05% ± 1.04 ± 0.08 3.95% ± 1.02 ± 0.06 . 3.96%± 
PBS+ Saline 0.22% 0.25% 0.28% 
3.95 ± 15.18% ± 3.91 ± 0.15 15.26% ± 3.74 ± 0.30 -114.80% ± 
100 LPS + PBS 0.17 0.45% 0.30% 0.71% 
2.08 ± 0.23 8.5%± 2.05 ± 0.19 8.3%± 2.02 ± 0.37 8.1% ± %0.35 
Indo+ LPS %0.39 %0.34 
2.53 ± 0.24 8.7%± 2.33 ± 0.37 8.6%± 2.13 ± 0.20 8.5% ± 0.32% 
Anti IL-11 + 0.32% 0.33% 
LPS 
The osteoclast number (ON) and osteoclast surface of the calvarial bone surface in the 
mice challenged with low dose LPS (LPS 100, 100 µg/mouse ). All mice received one-
time dose of LPS or saline, which was followed by anti-IL-11 mAb (Anti-IL-11, 465 
µg/mouse x 4 injections), indomethacin (Indo, 50 µg/mouse x 9 injections) or PBS 
injections. Mice were sacrificed on day 5. Values represent means± SD and n = 7 for 
each group. 
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Table 3. incidence of osteoclast number and osteoclast surface in mice injected with 500 
ug ofLPS. 
Vehicle 
Wild type mice IL-lR IL-1R/TNFp55 
#OC % surface #OC % surface #OC % surface 
mice 
1.03 ± 0.05 4.05%± 1.04 ± 0.08 3.95% ±0.25% 1.02 ± 0.06 3.95%± 
PBS+ Saline 0.22% 0.28% 
7.51 ± 0.47 32.35% ± 4.41 ± 0.26 19.18% ± 4.26 ± 0.30 18.93% ± 
500LPS+PBS 1.65% 0.96% 0.85% 
2.46 ± 1.06 9.8%± 2.26 ± 0.88 8.6% ± 0.84% 2.09 ± 0.86 8.3% ± 0.86% 
lndo+ LPS 0.96% 
3.42 ± 1.02 14.06% ± 3.02 ± 0.89 11.04% ± 2.97 ± 0.79 10.06% ± 
Anti IL-11 + %1.04 %0.84 %0.54 
LPS 
The osteoclast number (ON) and osteoclast surface of the calvarial bone surface in the 
mice challenged with low dose LPS (LPS500, 500 µg/mouse ). All mice received one-
time dose of LPS or saline, which was followed by anti-IL-11 mAb (Anti-IL-11, 465 
µg/mouse x 4 injections), indomethacin (Indo, 50 µg/mouse x 9 injections) or PBS 
injections. Mice were sacrificed on day 5. Values represent means± SD and n = 7 for 
each group. 
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We previously demonstrated that interleukin-1 (IL-1) and tumor necrosis factor (TNF) activities only 
partially account for calvarial bone resorption induced by local application of lipopolysaccharide (LPS) in 
mice. The present study was undertaken to determine the role and relative contribution of IL-11 and prosta-
glandin(s) (PG[s]) in LPS-induced bone resorption in vivo. A one-time dose of LPS was injected into the 
subcutaneous tissue overlying calvaria of mice lacking IL-1 receptor type I (IL-1Rr 1-), mice lacking TNF 
receptor p55 and IL-lRI (TNFRp55-t- -IL-lRI- 1-), and wild-type mice. Mice were then treated with injections 
of anti-IL-11 monoclonal antibody (MAb), indomethacin, or phosphate-buffered saline (PBS) and sacrificed 5 
days later. Histological sections stained for tartrate-resistant acid phosphatase (TRAP) were quantified by 
histomorphometric analysis. At low doses of LPS (100 µglmouse), the percentages of bone surface covered by 
osteoclasts were found to be similar in three strains of mice. The increase was reduced by 37% with anti-IL-11 
MAb and by 46% with indomethacin. At higher doses of LPS (500 µg/mouse), we found an eightfold increase 
in these percentages in wild-type mice and a fivefold increase in these percentages in IL-lRI- 1- and TN-
FRp55-1- -IL-lRr1- mice after normalizing with the value from the saline-PBS control group in the same 
strain of mice. The increase was reduced by 55 and 69% in wild-type mice and by 50 and 57% in IL-lRI_,_ and 
TNFRp55_,_ -IL-lRI- 1- mice treated with anti-IL-11 MAb or indomethacin, respectively. Our findings 
suggest that in vivo, at low doses of LPS (100 µg/mouse), LPS-induced bone resorption is mediated by IL-11 
and PGs, while at high doses of LPS (500 µglmouse), it is mediated by IL-11, PGs, IL-1, and TNF signaling. 
IL-11 and PGs mediate LPS-induced bone resorption by enhancing osteoclastogenesis independently of the 
IL-1 or TNF signaling. 
Bone resorption is a feature of chronic inflammatory dis-
eases such as rheumatoid arthritis, osteomyelitis, bacterial ar-
thritis, and periodontitis (16). Periodontitis is a common in-
flammatory disorder that often leads to irreversible alveolar 
bone resorption and tooth loss among adults and is character-
ized as a peripheral infection involving species of gram-nega-
tive organisms (37). The key issue to be addressed in these 
diseases is how bacteria cause pathological bone loss. Lipo-
polysaccharide (LPS), a component of the outer membranes of 
all gram-negative bacteria (28), was the first bacterial compo-
nent shown to be capable of inducing bone resorption in vitro 
(16). Although LPS has been identified as a major bacterial 
bone-resorbing factor, the cellular mechanism by which LPS 
stimulates bone resorption has not been fully elucidated. Un-
derstanding the means by which LPS enhances bone resorption 
would provide an effective therapeutic strategy to prevent and 
treat bacterially induced bone resorption. 
It is known that LPS triggers the inflammatory process both 
locally and systemically and stimulates cytokine secretion (16, 
38). LPS may stimulate host cells, including gingival fibroblasts, 
fibroblastic cells in the periodontal ligament, recruited leuko-
cytes (monocytes and macrophages), or osteoblasts producing 
cytokines and local mediators (16, 27, 32, 35). The major ef-
fects of LPS are produced by mediators ( e.g., LPS-binding 
proteins, cytokines, prostaglandins, prostacyclins, and NO, 
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etc.). But the signal pathway by which LPS stimulates bone 
resorption is unclear. 
Our previous study (5) demonstrated the existence of two 
signal pathways in LPS-induced bone resorption in vivo: one at 
high LPS doses and one at low LPS doses. At higher concen-
trations of LPS, osteoclastogenesis and bone resorption are 
substantially mediated by interleukin-1 (IL-1) and tumor ne-
crosis factor (TNF) receptor signaling, but this signaling does 
not completely account for bone resorption at lower LPS con-
centrations. At lower LPS concentrations, additional media-
tors, working independently or in concert with IL-1 and TNF, 
appear to contribute to LPS-induced bone resorption in vivo. 
The present work is a follow-up of our previous study advo-
cating for the role of IL-11 and prostaglandin(s) (PG[s]) with 
IL-1 and TNF in LPS-induced bone resorption in an in vivo 
mouse model. 
There are two forms of biologically active IL-1 ( a and f3 
forms) and two homologous receptors for IL-1 (IL-1 type I 
receptor [IL-lRI] and type II receptor [IL-lRII]) that can bind 
either form of IL-1, although with different affinities (2). The 
type I receptor is capable of mediating a biological signal, while 
the type II receptor is thought to function as a decoy receptor 
(34). Two types of high-affinity receptors, p55 and p75, have 
been identified for TNF molecules. Most but not all TNF 
activity has been shown to be mediated by the TNF receptor 
p55 (TNFRp55) (25, 30, 31). Recent evidence obtained from 
mice lacking p75 suggests that p75 may act to suppress TNF-
mediated inflammatory responses (31). 
IL-11, a 178-amino-acid nonglycosylated peptide cytokine 
critical for osteoclast development (9), was initially isolated 
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from a bone marrow-derived stromal cell line (24). IL-11 be-
longs to a family of cytokines including IL-6, leukemia inhib-
itory factor, oncostatin M, ciliary neurotrophic factor, and car-
diotrophin 1, all of which signal through gp130 (12). IL-11 is 
not produced by monocytes or lymphocytes. Its expression is 
restricted to certain cells of the mesenchymal lineage, such as 
bone marrow stromal cells, osteoblasts (29), articular chondro-
cytes, synoviocytes, lung fibroblasts (15), and osteosarcoma 
cells (8). IL-11 receptor transcripts have been demonstrated on 
mature osteoclasts and osteoblasts in bone marrow cultures 
(29) and on osteoblastic and chondroblastic progenitor cells 
during mouse embryogenesis (17). Current research demon-
strated that IL-11 stimulates multinucleated osteoclast-like cell 
formation and bone resorption in a dose-dependent manner in 
cell and organ culture systems (9, 11, 29). 
PGs are ubiquitous local hormones that have long been 
known to exert important effects on the skeleton (26) and in 
immuno-inflammatory responses. Extensive clinical research 
over many years has also demonstrated a significant role of 
PGs in the pathogenesis of periodontal disease (13, 14, 18, 19). 
Elevated PGE 2 levels within the gingival crevicular fluid have 
been suggested as a reliable biochemical marker for periodon-
tal disease activity and severity (18-20). PGs are produced as 
the metabolites from arachidonic acid by two key enzymes, 
cyclooxygenase 1 and cyclooxygenase 2. Cyclooxygenase 1 is 
produced constitutively in many tissues and appears to repre-
sent an essential component of tissue homeostasis. In contrast, 
cyclooxygenase 2 is generally undetectable under physiological 
conditions and appears to be responsible for PGs in inflam-
mation. Indomethacin is a relatively nonselective inhibitor of 
both types of cyclooxygenase ( 40) and has been widely used in 
in vitro and in vivo studies. 
Interestingly, the systematic role and relative contribution of 
IL-11 and PGs (compared to TNF and IL-1) in the regulation 
of LPS-induced bone resorption in vivo remains unknown. 
Therefore, by using anti-IL-11 monoclonal antibody (MAb) 
and indomethacin, we investigated in the present study the 
relative role of IL-11 and PGs in the overall process of bone 
resorption at high and low doses of LPS in three strains of 
mice. Our data indicated that IL-11 and PGs are significant 
mediators of LPS-induced osteoclastogenesis and bone resorp-
tion in vivo and that they may act independently of IL-1 and 
TNF receptor signaling. 
MATERIALS AND METHODS 
Reagents and mice. Escherichia coli serotype O55:B5 LPS (catalog no. L2880; 
Sigma, St. Louis, Mo.) was dissolved in phosphate-buffered saline (PBS) (5 
mg/ml) by sonication for 2 min, aliquoted, and stored at -80°C until use. Before 
each injection, the stock solution was sonicated for 2 min again. Anti-IL-11 MAb 
11 h3/19.6.1. (murine immunoglohulin Gl), a gift of Genetics Institute, Inc. 
(Cambridge, Mass.), was freshly prepared at the concentration of 9.3 mg/ml in 
PBS before each injection according to Genetic Institute recommendations. 
Indomethacin ( 1-(p-chlorobenzoyl ]-5-methoxy-2-methylindole-3-acetic acid 
Sigma) was suspended at 1 mg/ml immediately prior injection (4). 
All procedures involving animals were approved by the Institutional Animal 
Care and Use Committee at Boston University School of Medicine. Three strains 
of mice were used in this study : transgenic mice with a targeted deletion of IL-1 
receptor type I {IL-lRI- 1-) and TNF receptor p55 and IL-lRI double knockouts 
(TNFRp55_,_ -IL-1RI_ 1_) were generously provided by J. Peschon (Immunex 
Corp ., Seattle, Wash) . Genetically matched wild-type C57BL/6 Xl29 hybrids 
were purchased from Jackson Laboratory (Bar Harbor, Maine) . Mice were 
between 8 and 12 weeks of age during the study. Regular mouse chow and water 
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were provided ad libitum. The genotypes of mutant mice were routinely con-
firmed by PCR of extracted DNA. Each strain of mice was randomly assigned 
into a group with a low dose of LPS (100 µg/mouse) or a high dose of LPS (500 
µg/mouse). Each group included four different arms : (i) LPS challenge followed 
by anti-IL-11 MAb (LPS-anti-IL-11), (ii) LPS challenge followed by indometh-
acin, (iii) LPS challenge followed by PBS (LPS-PBS), and (iv) saline challenge 
followed by PBS (saline-PBS), which served as a control. There were seven mice 
in each group. 
Calvarial bone injection. The injections were administered with a 30.5-gauge 
needle at a point on the midline of the skull located between the cars and eyes. 
LPS, anti-lL-11 MAb, indomethacin, or PBS was delivered in the space between 
the subcutaneous tissue and the periosteum of the skull. 
Prior to the first injection, all animals were anesthetized intraperitoneally with 
a ketaminc-xylazinc solution (a combination of 1 ml of kctaminc [Ketaset], 1 ml 
of xylazine [Rompum; Fisher, Columbus, Ohio], and 6 ml of sterile PBS [Gihco 
BRL, Grand Island, N.Y.]). Approximately 5 µI of anesthetic per gram of body 
weight was administered . The heads of the anesthetized mice were shaved. One 
dose of LPS (100 or 500 µg/mouse) or saline, each in a 100-µl volume, was 
injected subcutaneously and then immediately followed by a same-site injection 
(50 µI/mouse) of anti-IL-11 MAh (465 µg/mouse), indomethacin (50 µg/mouse), 
or PBS. For subsequent treatments, all mice were anesthetized via inhaled 
isofluranc prior to their injections . Thereafter , anti-IL-11 MAb (465 µg/mousc) 
or PBS, each in a volume of 50 µI/mouse, was administered subcutaneously every 
4 h for a total of four injections (total dose of 1.86 mg of anti-IL-11/mouse). 
Indomethacin (50 µg/mouse) or PBS was injected in a 50-µI volume every 8 h, for 
a total of nine injections (total dose of 450 µg of indomethacin/mouse) . Mice 
were sacrificed in a CO2 chamber 5 days after the first injection. 
Specimen preparation. The entire calvarial bone together with the overlying 
skin tissue wa~ dissected and fixed in freshly prepared paraformaldehyde {4% in 
PBS, pH 7.2) for 6 h at 4°C. The specimen was then washed with 5, 10, and 15% 
glycerol in PBS, each for 15 min, and decalcified in lmmunocal solution (Decal 
Corporation, Congers, N.Y.) for 3 days at 4°C with gentle stirring. After two 
washes with Immunocal Neutralizer Solution (Decal Corporation) for 20 min at 
4°C, the anterior half of the frontal bone and the posterior half of the occipital 
hone were trimmed off. The remaining calvarial hone , with its overlying skin 
tissue, wa~ immersed in 30% sucrose in PBS overnight and then transferred into 
-80°C prechilled 2-methyl-butane (Sigma, St. Louis, Mo.) and stored at -80°C 
until embedding. 
Histochemical staining. The calvarial bone with skin tissue was cut in half 
through the sagittal suture. The two halves were embedded side by side with 
HISTO PREP compound (Fisher Scientific, Hanover Park, Ill.). Serial sections 
(5 µm) were made by cryostat sectioning . Fifty slides were obtained for each 
specimen, and every 10th slide was kept for tartrate-resistant acid phosphatase 
(TRAP) staining. The TRAP staining solution was prepared as follows: 9.6 mg of 
naphtha! AS-BI phosphate substrate (Sigma) was dissolved in 0.6 ml of N,N-
dimethylformamide (Sigma) with 60 ml of 0.2 M sodium acetate buffer (pH 5.0; 
Sigma), which contained 84 mg of fast red-violet LB diazonium salt (Sigma), 58.2 
mg of tartaric acid (Sigma), and 240 µI of 10% MgCl2 • The mixture was filtered 
through a 0.22-µm-pore-size filter. Slides were incubated for 8 min in the staining 
solution at 37°C in the dark . The slides were then washed with water for 30 min, 
which was followed by counterstaining with hematoxylin for 5 to 6 min. 
Bone bistomorpbometry. For each animal, four slides, each containing two 
tissue sections with the largest number of osteoclasts (criteria described below) 
were analyzed by computer-assisted image analysis (Image Pro plus image soft-
ware 4.0; Media Cybernetics, Silver Spring, Md.). The bone surfaces in the three 
sutures {the coronal suture, the lambdoid suture and the suture between the 
interparietal and occipital bones) were studied. All of the osteoclasts counted in 
this study were mature osteoclasts and had to have met the following criteria: 
large multinuclcatcd cells, TRAP-positive staining, lying in apposition to a bone 
surface, and undergoing lacunar resorption (resorption in Howship lacunae) (3, 
36). For quantitative image analysis, three parameters were measured: (i) the 
percentage of bone surface covered by ostcoclasts, which is the sum of the length 
of the osteoclasts containing lacunae (active eroded area) divided by the total 
length of the suture bone surfaces (this parameter represents the extent of the 
bone resorption on the suture bone surfaces); (ii) the osteoclast number (ON) 
(also known as the osteoclast index), which is the number of osteoclasts per 
millimeter of the suture bone surfaces and reflects changes affecting osteoclast 
formation ; and (iii)the individual ostcocla~t activity (IOA) (in micrometers per 
cell), which is the length of lacunar resorption per ostc.oclast. By measuring the 
ON and the IOA we could know whether the changes in bone resorption were 
caused by osteoclastogenesis or by the activity of single osteoclasts. These his-
tomorphometric parameters adhere to the recommended An1crican Society of 
Bone and Mineral Research nomenclature (22, 23). 
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FIG. 1. Percentage of bone surface covered by osteoclasts in mice challenged with a low dose of LPS. All mice received a one-time low dose 
of LPS (100 µg/mouse) (LPSlO0) or saline, which was followed by anti -IL-11 MAb (four injections of 465 µg/mouse), indomethacin (Inda) (nine 
injections of 50 µg/mouse), or PBS injections. Mice were sacrificed on day 5. Bars represent means (error bars, SD), and n was 7 for each group. 
Symbols:** and***, P < 0.Gl and P < 0.001, respectively (for comparison with wild-type mice in the LPSl00+PBS group);#, P < 0.01 (for 
comparison with mice of the same strain in the other three groups). 
All slides were coded by one person and analyzed by another person. The 
results were verified by a second examiner. Intcrexamincr and intracxaminer 
variation was generally less than 10%. 
Statistics. Results are displayed as means :±: standard deviations (SD) . There 
were seven mice in each group (11 = 7). Analysis of variance was used to analyze 
differences among groups; in addition, Fisher 's one-way analysis of variance and 
an unpaired two-tailed Student's t test were performed to compare results be-
tween treatment groups, and statistical significance was assumed for probability 
values of :s;Q,05. 
RESULTS 
Note. The degree of increase was obtained by normalizing an 
experimental given value with the value from mice of the same 
strain in the saline-PBS group. Percent bone inhibition was 
obtained by determining the amount of bone resorption the 
given treatment prevented from occurring normalized against 
maximum bone resorption (mice treated with LPS (100 or 500 
µg/mouse [ each strain]), e.g., (value for LPS-PBS mouse group 
- value for test group/value for LPS-PBS group X 100). 
Percentage of bone surface covered by osteoclasts. The per-
centage of bone surface covered by osteoclasts reflects the 
extent of the bone resorption on the suture bone surfaces. A.6 
seen in Fig. 1, low doses of LPS (100 µg/mouse) induced 
approximately a 3.7-fold increase of this parameter in all three 
strains of mice relative to values obtained in the saline-PBS 
group (LPS-PBS versus saline-PBS, 15.2% :±: 0.5% versus 
4.1 % :±: 0.2% in wild-type mice and 15.3% :±: 0.3% versus 3.9% 
:±: 0.2% in IL-lRI- 1- mice; 14.8% :±: 0.7% versus 4% :±: 0.3% 
in TNFRp55_ 1_ -IL-lR1- 1- mice). In contrast, anti-IL-11 re-
duced osteoclast coverage by approximately 37% (all P < 
0.01), and indomethacin reduced the percentage of bone sur-
face covered by osteoclasts by approximately 46% (all P < 
0.001) in all three strains of mice. 
However, at high doses of LPS (500 µg/mouse) (Fig. 2 and 
3) an approximately eightfold increase in osteoclast coverage 
of bone surface in wild-type mice was observed (Fig. 2) (32.4% 
:±: 1.7% in the LPS-PBS group versus 4% :±: 0.2% in the 
saline-PBS group). This is in contrast with an about fivefold 
increase observed with high-dose LPS challenge in either IL-
lR1-1- (19.2% :±: 1.0% in the LPS-PBS group versus 4.1 % :±: 
0.2% in the saline-PBS group) or TNFRp55_ 1_ -IL-lR1- 1-
mice (18.9% :±: 0.9% in the LPS-PBS group versus 4.0% :±: 
0.3% in the saline-PBS group). As shown in Fig. 2, in wild-type 
mice anti IL-11 antibody reduced bone resorption by 55% (P < 
0.001), while indomethacin reduced resorption by 69% (P < 
0.001). Bone resorption was inhibited by 50% (P < 0.01) using 
IL-11 antibody and by 57% (P < 0.01) using indomethacin in 
both IL-lRi- 1- mice and TNFRp55_ 1_ -IL-1RI_ 1_ mice. 
ON. Figure 3 illustrates light micrographs of mouse calvaria 
injected with 500 µg of LPS and subjected to the various other 
treatments. 
Figure 4 shows that the lower dose of LPS similarly in-
creased the ON by about 3.7-fold (for all results, P < 0.05) in 
all three strains of mice ( 4.0 :±: 0.2 versus 1.0 :±: 0.1 in wild-type 
mice, 3.9 :±: 0.2 versus 1.0 :±: 0.1 in IL-lRi- 1- mice, 3.7 :±: 0.3 
versus 1.0 :±: 0.1 in TNFRp5s - 1- -lL-lRi- 1- mice). However, 
the ON was reduced by about 38% with anti-IL-11 MAb (for 
all results, P < 0.01) and by around 52% with indomethacin 
(for all results, P < 0.001) in all three strains of mice. At high 
doses of LPS (Fig. 5), the ON increased by 7.3-fold in wild-type 
mice (7.5 :±: 0.5 versus 1.0 :±: 0.1 in wild type) and by 4.2-fold in 
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FIG. 2. Percentage of bone surface covered by osteoclasts in mice challenged with a high dose of LPS (500 µg/mouse (LPS500]). The treatm ents 
are identical to those described in the legend to Fig. 1. Bars represent means (error bars , SD), and n was 7 for each group . Inda , indomethacin. 
Symbols:@ , P < 0.001 (for comparison with all other groups in this figure) ; #, P < 0.01 (for comparison with mice of the same strain in the other 
three groups; *, P :5 0.05 (for comparison of mice of the same strain in the LPS500+Anti -IL-ll group and the LPS500+ Indo group). 
two strains of knockout mice( 4.4 ± 0.3 versus 1.0 ± 0.1 in 
IL-lRI - 1- mice; 4.3 ± 0.3 versus 1.0 ± 0.1 in TNFRp55 _1_ -
IL-lRI - 1- mice). However, anti-IL-11 MAb caused a 52% 
reduction of the ON in wild-type mice and a 30% reduction in 
two strains of knockouts (for all results, P < 0.01). At high 
doses of LPS, indomethacin inhibited LPS-induced ON by 
69% in wild-type mice and by 51 % in IL-lRI - 1- and TN-
FRp55 _1_ -IL-lRI - 1- mice, respectively (for all results, P < 
0.001). 
IOA. The results of IOA indicated that PGs, IL-1, and TNF 
signaling did not affect the regulation of resorptive activity of 
single osteoclasts in LPS-induced bone resorption, since no 
significant differences were found among the three strains of 
mice with or without indomethacin treatment. However, the 
IOA (in micrometers per cell) was greater in response to 
high-dose LPS than to low-dose LPS in aU three strains of mice 
(high-dose LPS-PBS versus low-dose LPS-PBS group: 43.8 
±2.0 versus 36.9 ± 1.5 in wild-type mice, 44.8 ± 3.6 versus 35.7 
± 1.9 in IL-lRI - 1- mice, and 42.5 ±2.3 versus 36.5 ±2.2 in 
TNFRp55 _1_ -IL-lRI - 1- mice (for all results, P < 0.05]), and 
all LPS-PBS-treated groups had greater IOA values than were 
seen in saline-PBS controls (saline-PBS group: 32.4 ± 1.1 in 
wild-type mice, 31.3 ± 1.8 in IL-1- 1- mice, and 31.6 ± 1.2 in 
TNFRp55 -t- -IL-lR1 - 1- mice [for all results, P < 0.05]). IL-
11, however, appeared to mediate bone resorption induced by 
high doses of LPS not only by prompting osteoclastogenesis 
but also by increasing the resorptive activity of single oste-
oclasts, since the JOA was lower in high-dose-LPS-anti-IL-11 
groups than that in high-dose-LPS-PBS groups in three strains 
of mice (LPS-anti-IL-11 versus LPS-PBS: 36.5 ± 1.1 versus 
43.8 ±2.0 in wild-type, 34.8 ± 1.0 versus 44.8 ± 3.6 in IL-1- 1-
mice, and 37.0 ±2.0 versus 42.5 ±2.3 in TNFRpss - 1- -IL-
lR1 -1- mice [for all results, P < 0.05]). 
DISCUSSION 
Since virtually complete inhibition of cytokine activity can be 
obtained when cytokines or cytokine receptors are genetically 
deleted from experimental animals, targeted deletions of IL-1 
and TNF receptors have been invaluable tools in dissecting the 
roles of these cytokines in disease processes, particularly in the 
inflammatory response to LPS (10, 25). In this study, IL-
lRi-1 - mice and TNFRp55 -t- -IL-lRI - 1- mice were used. 
Although LPS is identified as the major bacterial bone-
resorbing factor, surprisingly little is known about its mecha-
nism of action (16). Although several cytokines and local fac-
tors, such as IL-1, IL-11, TNF, and PGs, have been reported to 
stimulate osteoclastogenesis and bone resorption in ceU and 
organ culture systems (9, 14, 16, 21, 36, 39), little is known 
about their in vivo role and contribution in the regulation of 
LPS-induced bone resorption. In our previous study, we have 
suggested two different pathways in LPS-induced bone resorp-
tion in vivo (5). The present data substantiate our previous 
finding (5) that at high doses of LPS, LPS-induced bone re-
sorption is mediated at least in part by IL-1 and TNF receptor 
signaling, but that this is not true at low LPS doses. Further-
more, the fact that low-dosage-LPS challenge affected all three 
strains of mice similarly confirmed the fact that in under these 
conditions LPS-induced bone resorption proceeds through a 
pathway independent of IL-1 and TNF signaling. The present 
in vivo study further demonstrates that (i) at low doses of LPS, 
LPS-induced bone resorption is influenced by IL-11 and PGs, 
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FIG. 3. Light micrographs of mouse calvaria injected with 500 µg of LPS and treated with either PBS (panels 1), anti-IL-11 MAb (panels 2) , 
or indomethacin (panels 3) in wild-type (A), IL-lRI_,_ (B), and TNFRpss- 1- -IL-lRI _,_ (C) mice. Histological sections of the calvarial bone were 
stained for TRAP and counterstained with hematoxylin. An arrow indicates TRAP-positive (red-staining) multinucleated cells in Howship 's 
lacunae. Abbreviations : BM, bone marrow; Inda, indomethacin . Magnification, X200. 
while at high doses it is mediated by IL-11, PGs, and IL-1 
receptor signaling; (ii) IL-11 and PGs increase LPS-induced 
bone resorption by pathways independent of IL-1 or 1NF 
receptor signaling; and (iii) IL-11 and PGs increase LPS-in-
duced bone resorption by enhancing osteoclast formation. In 
addition, IL-11 was involved in bone resorption induced by 
high-dose LPS by enhancing the resorptive activity of individ-
ual mature osteoclast. The present study provided the relative 
contribution of each mediator-IL-1, 1NF, IL-11, and 
PGs-in LPS-induced bone resorption in vivo. Since bone re-
sorption was affected similarly in IL-lRI_,_ mice and 1N-
FRp55_, _ -IL-lRi- 1- mice, a minor role of 1NF receptor 
signaling is advocated in LPS-induced bone resorption. How-
ever, caution must be exercised in extrapolating these obser-
vations to humans given the potential compensatory mecha-
nisms that may exist in IL-lRI_,_ and lNFRpss - 1- -IL-
lRi-1- mice. 
Regarding signal transduction pathways, osteoclast forma-
tion is induced by at least three different mechanisms. The first 
mechanism involves the gp130 signal, an important pathway of 
osteoclast formation, which is activated by cytokines such as 
IL-11, IL-6, and leukemia inhibitory factor. The second mech-
anism is the parathyroid hormone-IL-1-PGE axis, which is 
mediated by signaling involving cyclic AMP. The third mech-
anism is lcx,25-dihydroxyvitamin D3-induced osteoclast forma-
tion, which is mediated by the vitamin D receptor but inde-
pendent of cyclic AMP (11, 36, 41). In addition, several in vitro 
studies have found that IL-11 stimulated osteoclast formation 
in a dose-dependent pattern (9, 11, 29) and was unaffected by 
inhibitors of IL-1 and 1NF (9). Other in vitro studies have also 
found that LPS stimulated bone resorption by a PGE 2-depen-
dent mechanism in mouse bone marrow culture systems (39) 
and that IL-1 and 1NF mediate osteoclastogenesis and bone 
resorption through PGs, since IL-lex and 1NF alpha enhanced 
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FIG. 4. ON of the calvarial bone surface in mice challenged with a low dose of LPS. All mice received a one-time dose of LPS (100 µg,,'mouse) 
(LPSlO0) or saline, which was followed by anti-IL-11 MAb (four injections of 465 µg,,'mouse), indomethacin (Inda) (nine injections of 50 
µg/mouse), or PBS injections. Mice were sacrificed on day 5. Bars represent means (error bars, SD), and n was 7 for each group. Symbols: ** and 
*** P < 0.0l and P < 0.001, respectively (for comparison with wild-type mice in the LPSlO0+ PBS group) ; #, P < O.Dl (for comparison with mice 
of the same strain in the other three groups). 
osteoclast formation in a dose-responsive manner which was 
inhibit ed by indomethacin and reversed by addition of exoge-
nous PGE 2 (1, 14). Therefore, IL-11 and PGs may mediate 
osteoclastogenesis independent of IL-1 and TNF signaling to 
prompt LPS-induced bone resorption in vivo. 
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Our findings also indicate that PGs have a potentially stron-
ger activity than IL-11 in LPS-induced bone resorption and 
osteoclastogenesis in vivo. PG s have been previously found to 
be essential for osteoclast formation in vitro. Without PGs, 
osteoclast formation and bone resorption are virtually nonex-
.... ........... # . 
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FIG. 5. ON of the calvarial bone surface in mice challenged with a high dose of LPS (500 µg,,'mouse [LPS500]) . The treatments are identical 
to those described in the legend to Fig. 4. Bars represent means (error bars , SD), and n was 7 for each group. Inda, indomethacin. Symbols: @, 
P < 0.01 (for comparison with all other groups in this figure);# , P < 0.001 (for comparison with mice of the same strain in the other three groups) . 
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istent in cell and bone organ culture systems (6, 7, 33). Recent 
findings demonstrate that IL-11 effects on osteoclast formation 
were prevented by indomethacin in vitro (9, 11), indicating 
that, as for IL-1 and TNF (14), the stimulatory effects of IL-11 
also involved products of arachidonic acid metabolism (11). 
Therefore, the stronger ability of indomethacin in reducing 
bone resorption and osteoclastogenesis may have resulted 
from inhibition of not only PGs but also other cytokines (such 
as IL-11 and IL-1) which can mediate their effects through PGs 
in vivo. 
Bone resorption is characterized by numerous sequential 
events, including osteoclast formation (proliferation, differen-
tiation, and fusion), (pre)osteoclast migration to future resorp-
tive sites, and osteoclast resorptive activity (3, 11, 36). The 
present study found that anti-IL-11 MAb reduced the JOA in 
high-dose-LPS groups. This indicates that IL-11 is involved in 
bone resorption induced by high doses of LPS not only by 
augmentation of osteoclastogenesis but also in altering the 
resorptive activity of individual mature osteoclasts. Since IL-11 
receptor transcripts were detected in mature osteoclasts, this 
indicates that mature bone-resorbing cells are potential targets 
of IL-11 (29). In addition, our results show that IL-11 was 
involved in mediating the resorptive activity of individual os-
teoclasts only after high-dose LPS challenge, which suggests 
that there might be a critical threshold of the sensitivity of 
osteoclast activity for IL-11. Taken together, these results sug-
gest that IL-11 is an important mediator in bone resorption 
cascades independent of IL-1 and TNF receptor signaling in 
LPS-induced inflammatory bone resorption. 
Conclusions. In the present report, an attempt has been 
made to address the pathway connecting LPS to bone resorp-
tion and elucidate the role of IL-11, PGs, IL-1 signaling, and 
TNF signaling in LPS-induced bone resorption. In addition the 
relative role of each of these factors in the overall process of 
bone resorption for groups treated with high and low doses of 
LPS was determined. At low doses of LPS, osteoclastic bone 
resorption was caused primarily by enhanced osteoclastogen-
esis, and this effect was mediated only by IL-11 and PG sig-
naling. These data suggest that in chronic bone diseases in-
volving challenge with low doses of LPS ( e.g., periodontal 
disease), LPS-induced bone resorption results from the effect 
of IL-11 and PGs on osteoclasts. In contrast, at high doses of 
LPS, LPS-induced bone resorption appeared to be mediated 
by a combination of IL-11, PGs, and IL-1 receptor-based sig-
naling. Indomethacin showed slightly stronger activity in re-
ducing LPS-induced osteoclastogenesis and bone resorption 
than did anti-IL-11 MAb. IL-11, however, appeared to mediate 
bone resorption induced by high doses of LPS not only by 
prompting osteoclastogenesis but also by increasing the resorp-
tive activity of single osteoclasts. These data suggest that in 
acute bone resorption processes involving high doses of LPS 
( e.g., periodontal abscesses) LPS-induced bone resorption re-
sults from the combinatorial effects of IL-1, IL-11, and PGs. 
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